Term	Prime number	Relation	Modified Gödel Number

Term1	2

Term2	3	R1: Term2 is a Term1	relation(is a) = 3 × 2 = 6

Term3	5	R2: Term3 is part of Term2	relation(part of) = 5 × 3 × 2 = 30

Term4	7	R3: Term4 is a Term2	relation(is a) = 7 × 3 × 2 = 42


Table 3	All grades	Grade 3

	n	%	n	%

Skin	5	19	1	4

Lymph edema	3	12

Dysphagia	2	8	1	4

Xerostomia	8	31

Loss of taste	4	15

Hearing loss	3	12	2	8

Sinusitis	1	4	1	4

Hypothyreosis	1	4

Hoarseness	1	4

Dry eye	1	4

Skin infection*	1	4	1	4

Trismus	1	4


S.n	Criterion	Sensitivity	Specificity	PPV	NPV

1.	Size > 6 cm	0.95	0.57	0.67	0.93

2.	Size >8 cm	0.75	0.76	0.75	0.76

3.	Shape: irregular, lobulated	0.83	0.76	0.76	0.83

4.	Margins: infiltrative	0.91	0.65	0.70	0.89

5.	Isointensity on T1W	0.70	0.76	0.73	0.74

6.	Slight hyperintensity on T2W	0.95	0.38	0.58	0.90

7.	heterogeneous lesion	1	0.5	0.64	1

8.	Peritumoral edema	0.95	0.5	0.63	0.92

9.	Absence of multiplicity	0.54	0.15	0.37	0.26

10.	Intratumoral necrosis	0.87	0.84	0.84	0.88

11.	Intratumoral hemorrhage	0.70	0.65	0.65	0.70

12.	Intratumoral calcification	0.70	0.88	0.85	0.76

13.	Absence of Intratumoral fat	1	0.07	0.5	1

14.	Absence of Intratumoral fibrosis	0.87	0.03	0.45	0.25

15.	Fascia penetration	0.83	0.73	0.82	0.74

16.	Bone changes	0.83	0.84	0.83	0.84

17.	Neurovascular involvement	0.83	0.88	0.86	0.85

18.	Enhancement pattern (Heterogenous)	1	0.07	0.5	1

19.	Absence of T1 hyperintense tracts	1	0.11	0.51	1

20.	Absence of Fluid-fluid levels	0.83	0.26	0.51	0.63


Health outcome	Studies exploring associations with weather/climate	Studies projecting the health impacts of climate change

Heat waves	++	+

Other extreme events	+	0

Waterborne and foodborne diseases	++	0

Vectorborne and zoonotic diseases	+	0

Air pollution (limited areas)	++	+

Aeroallergens	+	0

Other health impacts including mental health, nutritional issues related to food security, and population displacement	+	0


 	First assessment, first test (n = 63)	First assessment, second test (n = 63)	P-value for group difference†	Second assessment, first test (n = 61)	Second assessment, second test (n = 61)	P-value for group difference†

Neck flexor muscle endurance test (supine), holding time, sec	36.40 (33.25)	30.92 (25.92)	0.305	34.03 (23.74)	38.10 (33.94)	0.445

Neck flexor muscle endurance test (sitting 45°), holding time, sec	82.33 (57.23)	72.70 (52.83)	0.328	102.11 (82.34)	85.13 (57.81)	0.190

Neck extensor test, holding time, sec	36.21 (25.09)	33.51 (23.56)	0.535	37.02 (28.39)	38.34 (25.72)	0.787


microRNA	Inhibitor Agent	Type of Disease	Investigation Status	Company/Ref

miR-10b	ASO	Glioblastoma	Preclinical	Regulus Therapeutics [108]

miR-21	ASO	HCC, fibrosis	Preclinical	Regulus Therapeutics [109,110]

miR-155	LNA-modified	T cell lymphoma and mycosis fungoides	Phase I	miRagen Therapeutics [111]

miR-221	ASO	Pancreatic carcinoma	Preclinical	Regulus Therapeutics [110]

miR-122	LNA-modified	HCV	Phase II	Santaris Pharma [112,113]


Evidence code type	Evidence code	Annotation errors	Total annotations	Percentage error rate

Experimental(manually assigned)	EXP	977	5360	18.23

	IDA	12	105764	0.01

	IMP	84	88283	0.10

	IEP	0	10129	0.00

	IPI	0	29877	0.00

	IGI	0	12914	0.00

Computational Analysis(manually assigned)	ISS	85	228605	0.04

	ISO	1	2975	0.03

	ISA	0	5921	0.00

	ISM	0	143	0.00

	IGC	0	483	0.00

	RCA	3	75175	0.00

Author statement(manually assigned)	TAS	4070	46888	8.68

	NAS	3	23578	0.01

Curator statement(manually assigned)	IC	0	5682	0.00

	ND	0	171817	0.00

Automatically Assigned	IEA	639	844441	0.08


Image	Speed up

Spine (MRI)	32.7%

Chest (X-ray)	33.1%

Fetus (ultrasonic)	52.7%

Head (CT)	53.6%


Primer target	Primer sequence (5′ to 3′)

Pgc-1α-a F	GCTTGACTGGCGTCATTCG

Pgc-1α-a R	ACAGAGTCTTGGCTGCACATGT

Pgc-1α-b F	GACATGGATGTTGGGATTGTCA

Pgc-1α-b R	ACCAACCAGAGCAGCACATTT

Pgc-1α-c F	AGTGACATGGATGTTGGGATTG

Pgc-1α-c R	GAATGCCTCCGGTTACTCACTT

Pgc-1α4 F	TCACACCAAACCCACAGAAA

Pgc-1α4 R	CTG GAA GAT ATG GCA CAT

FL-Pgc-1αF	TGCCATTGTTAAGACCGA

FL-Pgc-1αR	CCAGAGTCACCAAATGACC

total NT-Pgc-1α F	TGCCATTGTTAAGACCGA

total NT-Pgc-1α R	CCATATCTTCCAGTGACC

total Pgc-1α F	TGATGTGAATGACTTGGATACAGACA

total Pgc-1α R	GCT CAT TGT TGT ACT GGT TGG ATA TG


Components	Composite Alpha	Extracted variance	Interobserver Reliabilitya	Item	Standb	Var. Error	Factor loadingc	Convergent validityd	Discriminant validity

Component 1	0.79	0.56	84.9	Inflammation	0.59	0.65	0.59	4.64	0.50

Edema	0.74	0.45	0.74	6.11

Pain	0.89	0.21	0.81	6.68

Component 2	0.71	0.55	87.9	Abscess	0.71	0.49	0.78	5.24

Alveolar osteitis	0.78	0.39	0.78	5.74


	Study period (weeks)

Time point	3/16	4/16	5/16	6/16	7/16	8/16	9/16	10/16	11/16

Enrolment

 Recruitment	X	X	X	X

 Eligibility screen	X	X	X	X

 Informed consent	X	X	X	X

 Allocation	X	X	X	X

Interventions:

 Discussion group	X	X	X	X	X	X

 Minimal support group (MSG)	X	X	X	X	X	X

 Wait list control group (access to MSG)					X	X	X	X	X

Assessments

 T1	X	X	X	X

 Credibility/expectancy	X	X	X	X	X

 T2			X	X	X

 T3					X	X	X

 Study completion									X


Current year	Next year

Breeders, %	N	Failed breeders, %	N

Breeders	78.9	172	21.1	46

Failed breeders	82.0	50	18.0	11


	Mean	SD	Range	Skewa	Kurtosisa

Adolescent self‐worth	26.85	4.53	16–46	−0.47 (−0.46)	3.31 (3.30)

Parent report parent–child closeness	39.09	4.66	21–50	−0.09 (−0.08)	2.75 (2.76)

Parent report expressions of affection	57.35	14.55	23–123	0.41 (0.45)	3.08 (3.34)


Subthemes	Data extracts

4.1 Lack of empathy with the challenges of medication usage	‘ ... They don't understand that you are wearing stuff on your head that makes you smell like you're painting fences ... it's really frustrating, they [clinicians] need to look at the impact of these treatments, maybe then they could understand why people aren't sticking to them.’ [P11: using topical therapy]

‘My [GP] said, “Well use the coal tar during the day,” and I said, “Well I can't because it's too messy ... ,” and all she said was “Oh, well just wear gloves.” But it's impossible as I'm working with papers all the time.’ [P9: prescribed topical therapy but using herbal therapies]

‘It did kind of put me under a bit of stress, it affected my condition hugely. I really don't understand why [I was unable to be prescribed my preferred biologic], I mean, I try not to think about it too much but at the time it did cause me a lot of worry and upset ... there might have been a very good reason behind it but they didn't want to share it with me.’ [P3: prescribed a biologic]

‘I had to really look [possible side‐effects] up myself on the Internet. She [clinician] was quite blasé about it ... and I was reading all these blogs about side‐effects which worried me, so I wasn't happy that I wasn't getting all the information.’ [P13: using topical and oral therapy]

‘Nobody has ever really asked me how I feel about my psoriasis or how I deal with my psoriasis. Or what my feelings are. Nobody has ever asked me that.’ [P15: using topical therapy and photochemotherapy]

4.2 Lack of support reinforced rejection of psoriasis therapies	‘I stopped going [to the GP] because they weren't helping ... because nothing [treatment] had worked there wasn't really much point in trying another one.’ [P9: prescribed topical therapy but using herbal therapies]


Anatomical region	L/R	Cluster level P(corrected)	Size (voxels)	Voxel level P (FDR-corrected)	Voxel level P (uncorrected)	MNI (mm) x y z	Voxel Z

Limbic lobe uncus	Left	0.015	92	0.232	0.000	−18	2	−22	4.13

Middle Frontal gyrus	Left	0.083	66	0.018	0.000	−18	46	−14	5.21

Cerebellum posterior Lobe	Right	0.025	89	0.125	0.000	26	−34	−40	3.98


Landscape characteristics	Definition

Habitat types

 Floodplain	Open, seasonally flooded grasslands

 Grassland	Open, shrubbed, savannah grasslands

 Acacia woodland	Open woodland with >70% Acacia species

 Riparian woodland	Tall open mixed woodland located in riverine or historic riverine areas

 Mopane woodland	Colophosphermum mopane dominated woodland

Landscape metrics

 Number of habitat patches (NP)	Measure of landscape fragmentation; metric equals the number of patches in the landscape. Value ranges from 1 if one patch covers entire landscape to a maximum equal to the total number of patches

 Landscape mean patch shape index (MSI)	Measure of the average patch complexity within the landscape; metric equals 1 if average patch is square, increasing without limit as shape becomes more irregular

 Index of juxtaposition and interspersion (IJI)	Measure of the intermixing of different habitat patches; probabilistic metric equals 0 if some habitat types are commonly found adjacent to each other but others are rarely found adjacent to each other, ranging to 100 when all habitat types are equally adjacent to all other habitat types


Clinical features	Patients at onset n	Cumulative number of patients at eight years n

Dactylitis	15	24

Nail pitting	10	18

Psoriasis	11	14

Psoriasis-like rash	6	13

Enthesitis	37	41


	Model definition(relevant year in brackets)	External data definition(data source in brackets)

Incidence	OUTCOME: Incidence of first AMI (2010)	Incidence of first AMI since 1998 (linked hospital episodes and mortality statistics, 2010).

Prevalence	Prevalence of ever having had an AMI (2010)	Prevalence of ever having had a doctor-diagnosed AMI (Health Survey for England, 2011).

Remission	Zeroa	Zero

Excess mortality	Excess mortality due to first AMI (2010)	Death where AMI is included anywhere on the death certificate (ONS mortality statistics, 2010).


Characteristics	Potential patients (n = 10)	Therapists (stage 1) (n = 4)	Therapists (stage 3) (n = 5)

	n	%	n	%	n	%

Sex

 Male	2	20	2	50	2	40

 Female	8	80	2	50	3	60

Age (in years)

 18–30	2	20	0	0	0	0

 30–50	4	40	2	50	3	60

 50–70	4	40	2	50	2	40

Nationality

 British	10	100	4	100	5	100

Highest level of education

 < A-levels	1	10	0	0	0	0

 A-levels	2	20	0	0	0	0

 University degree	5	50	1	25	1	20

 Post-graduate diploma	0		1	25	2	40

 Post-graduate degree	1	10	1	25	1	20

 Doctoral degree	1	10	1	25	1	20

Mental health problem

 Depression	10	100	N/A	N/A

 Anxiety	8	80	N/A	N/A

Previous therapy experience

 None	4	40	N/A	N/A

 Cognitive behavioural therapy	4	40	N/A	N/A

 Mindfulness-based cognitive therapy	3	30	N/A	N/A

 Behavioural activation	1	10	N/A	N/A

 Interpersonal psychotherapy	1	10	N/A	N/A

Area(s) of clinical training

 Cognitive behavioural therapy	N/A		4	100	5	100

 Behavioural activation	N/A		4	100	4	80

 Eye movement desensitisation and reprocessing	N/A		1	25	2	40

 Interpersonal psychotherapy	N/A		1	25	1	20

 Dialectical behaviour therapy	N/A		1	25	1	20


Host	Bacteria	Effective against	Active compound	Reference

Barnacle B. amphitrite	Vibrio, Alteromonas, Alcaligenes, Flavobacterium, and Pseudomonas	Barnacle B. amphitrite	?	Mary et al. (1993)

Algae, sponges, and ascidian Ciona intestinalis	Pseudomonas aurantia, P. citrea, P. piscicida, P. rubra, P. undina, P. ulvae, P. haloplanktis, P. luteoviolacea, P. tunicata, P. nigrifaciens	Polychaeta, Hydroides elegans, barnacle Balanus amphitrite, and ascidian Cliona intestinalis	?	Holmström and Kjelleberg (1999), Holmström et al. (2002)

Nudibranch Archidoris pseudoargus	Pseudomonas sp.	Barnacle Balanus amphitrite	Phenazine-1-carboxylic acid, 2-n-hyptyl quinol-4-one, 1-hydroxyphenazine phenazine-1-carboxylic acid, pyolipic acid	Burgess et al. (2003)

Green alga Ulva reticulata	Vibrio alginolyticus	Polychaeta, Hydroides elegans	Polysaccharide >200 kDa consist of glucose, mannose, galactose, and glucosamine	Dobretsov and Qian (2002), Harder et al. (2004)

Soft coral Dendronephthya sp.	Vibrio sp., uncultured Ruegeria, unidentified a-Proteobacterium	Polychaeta, Hydroides elegans, bryozoan Bugula neritina	?	Dobretsov and Qian (2004)

Sponge Halichondria okadai	Alteromonas sp.	Barnacle B. amphitrite	Ubiquinone	Kon-ya et al. (1995)

Ascidian Stomozoa murrayi	Acinetobacter sp.	Barnacle B. amphitrite	6-bromindole- 3-carbaldehyde	Olguin-Uribe et al. (1997)

Green alga Ulva australis	Pseudoalteromonas tunicata and Phaeobacter sp. strain 2.10	Bryozoan Bugula neritina	?	Rao et al. (2007)

Brown alga Fucus serratus, F. vesiculosus, and the red alga Polysiphonia stricta	Natural communities, Photobacterium halotolerans and Ulvibacter litoralis, Shewanella basaltis, Pseudoalteromonas arctica, Shewanella baltica, and Bacillus foraminis	Barnacle Amphibalanus improvisus	?	Nasrolahi et al. (2012)

Sponge Lissodendoryx isodictyalis	Winogradskyella poriferorum	Polychaete H. elegans and barnacle B. amphitrite	Poly-ether AE	Dash et al. (2009), Dash et al. (2011)


Gene	Forward primer	Backward primer	Size (bp)

GAPDH	GGTCGTATTGGGCGCCTGGTC	TGACGGTGCCATGGAATTTGCCA	148

KIFC1	TCTCTGGGTGGTAGTGCTAAGA	TAAGTCACTTCCTGTTGGCCTG	148

SOX4	GACCGGGACCTGGATTTTAACT	TGAAAACCAGGTTGGAGATGCT	133

PBX2	AAGTTCCAAGAGGAGGCAAACA	TCCTGAGAGATTGAAAGAGCCG	132

ESRRG	GCTATCCTGCAGCTGGTAAAGA	GCTATCCTGCAGCTGGTAAAGA	133

KDM5B	CCCTCAGACACATCCTATTCCG	CAGTCCACCTCATCTCCTTCTG	101

PTGS2	TGTATCCTGCCCTTCTGGTAGA	AAGGAGAATGGTGCTCCAACTT	85

EFNA1	GTGGCAAAATCACTCACAGTCC	CTATGTAGAACCCGCACCTCTG	91

BCL2	AGGATTGTGGCCTTCTTTGAGT	CGGTTCAGGTACTCAGTCATCC	113

SMAD4	TGTTGATGACCTTCGTCGCTTA	ATGCTCTGTCTTGGGTAATCCG	81

PHACTR3	TATGACAGGAGGGCAGACAAAC	GCTTGCTTGATGCATGTACCTC	118

C13orf27	TCAGGCTCAGCAGATGAAATGT	TCCAGTGGATTTTATGGGGAGC	85

PMEPA	CTGAGCCACTACAAGCTGTCTG	CTTCTGAGGACAGGGCATCTTC	85

OXGR1	ATCTTGAGGGTCATTCGGATCG	TGTCGCTGACCACCACATATAG	148

GPNMB	GTCACTGTGATCTCCCTCTTGG	TTTGCACGGTTGAGAAAGACAC	116


Predictors	OR	95% CI	p-Value	Nagelkerke R2

Perceived benefits of HSIV:				0.631

HSIV can prevent children from catching Influenza	2.367	(1.272, 4.404)	0.007

Perceived barriers of HSIV:

The HSIV will cause unknown side effects to children	0.321	(0.149, 0.691)	0.004

Motivating factors of vaccination taking:	3.675	(1.745, 7.742)	0.001

You would be more willing to give your children HSIV shots if the injection was cheap


References	SCI model	Methods	LncRNA expression changes

Animal	Method	Level	Sampling

35	Adult female SD rats (200–250 g)	Contusive spinal cord injury using an NYU impactor (10 g, 12.5 mm)	T10	1, 4 and 7 days post‐SCI	RNA sequencing	1 dpo: 1 down, 6 up4 dpo: 5 down, 2 up7 dpo: 5 down, 2 up

33	Male ICR mice (20–25 g) aged 6–8 weeks	Multicenter Animal Spinal Cord Injury Study (MASCIS) Impactor weight‐drop device(5 g, 25 mm)	T10	1 day, 3 days, 1 week and 3 weeks post‐SCI	Microarray	1 dpo: 181 down, 164 up3 dpo: 290 down, 212 up1 wpo: 565 down, 326 up3 wpo: 40 down, 141 up

34	Adult female SD rats aged 12–14 weeks	Moderate contusion injury	T9	1, 3 and 6 months post‐SCI	RNA sequencing	1mpo: 17 down, 120 up3mpo: 77 down, 162 up6mpo: 54 down, 125 up


Characteristics of preliminary categories	Final categories	1999/2000	2005	2010

		n	%	n	%	n	%

Permanent work	Non-precarious employment (NP)	575	50.7	739	65.1	859	75.7

 + no or low self-rated risk of future unemployment (regardless of previous unemployment)

Contingent work	Non-precarious employment (NP)	82	7.2	27	2.4	16	1.4

 + no self-rated risk of future unemployment+ no previous unemployment

All others with contingent work AND/OR moderate to high self-rated risk of future unemployment AND/OR previous unemployment	Precarious employment (PE)	416	36.6	306	26.9	207	18.2

Unemployed	Precarious employment (PE)	62	5.5	63	5.6	53	4.7

		1135	100	1135	100	1135	100


	Did not participate Patella lead level	Participated Patella lead level

Characteristic	Low (n = 90)	High (n = 103)	Low (n = 15)	High (n = 16)

Mean age in years ± SD at MRSa	73.0 ± 6.2	78.0 ± 5.9	73.2 ± 4.7	80.7 ± 6.1

Mean years ± SD of education	15.3 ± 2.5	13.2 ± 2.6	16.3 ± 3.1	13.4 ± 2.6

Mean ± SD serum creatinine (mg/dL)	1.1 ± 0.5	1.1 ± 0.3	1.0 ± 0.2	1.2 ± 0.4

Mean ± SD systolic blood pressure (mmHg)	134 ± 16	134 ± 17	133 ± 15	135 ± 20

Diabetes, n (%)	7 (8)	5 (5)	0	1 (6)

Hypertension, n (%)	28 (31)	36 (35)	4 (27)	7 (44)

Taking hypertension medication, n (%)	9 (10)	15 (15)	1 (7)	6 (38)

Myocardial infarction, n (%)	0	6 (6)	0	1 (6)

Stroke, n (%)	0	3 (3)	0	1 (6)

Median (IQR) patella lead (μg/g bone)	10 (6–14)	48 (44–60)	9 (5–15)	63 (43–86)

Median (IQR) tibia lead (μg/g bone)	11 (7–17)	32 (24–41)	13 (9–17)	41 (38–59)


	N	n female	Age range

Tutor: Medical Doctor	1	0	51

Tutors: CO/AMO	3	0	41 – 65

Tutor: Nurse	1	1	35

Students: First year	3	1	19 – 28

Students: Second year	3	1	22 – 35

Students: Third year	4	1	23 – 30


Predictors	df	AICc	ΔAICc	wi

Δ Latitude of the 80% diversity contour	3	−348.31	0.00	0.65

Δ Eastern U.S. winter temperature	3	−345.14	3.17	0.13

Null	2	−344.74	3.57	0.11

Global temperature anomaly	3	−342.55	5.76	0.04

Northern hemisphere temperature anomaly	3	−342.42	5.88	0.03

Eastern U.S. temperature anomaly	3	−342.42	5.88	0.03


Correction Method	Mean Error before Correction (mm)	Mean Error after Correction (mm)	Standard Deviation before Correction (mm)	Standard Deviation after Correction (mm)

Interpolation	2.737	0.325	2.781	0.549

Function (FFT)	2.737	0.400	2.781	0.581


	Test group*	Active control group*	Total

	N	Mean	SD	N	Mean	SD	N	Mean	SD

Usefulness of

Toothbrushing supplies	61	9.6	1.2	76	9.4	1.8	137	9.5	1.5

Printed postcard messages	54	7.2	3.6

Voice telephone messages	49	6.4	3.9

Overall satisfaction	61	9.5	1.1	76	9.5	0.9	137	9.5	0.9


Old name*	New name*

N.CglI	H.CglI

N.NgoAVII	H.NgoAVII


 Index 	 SS 	 df 	 MS 	 F 	 p

 Pre-tests and post-tests of interaction 	 34.16 	 1 	 17.08 	 0.10 	 0.900


Anterior wall

 TCC	16,5 μm

 Spectral estimation Burg 	19,5 μm

 Spectral estimation Yule-Walker	21,3 μm

Posterior wall

 TCC	16,5 μm

 Spectral estimation Burg	22,0 μm

 Spectral estimation Yule-Walker	17,0 μm


 	 	 	N (%)

Age, years	Median	63.0

Range	33–81

Sex	Male		31 (70.5%)

Female		13 (29.5%)

ECOG performance status	0		24 (54.5%)

1		15 (34.1%)

2		5 (11.4%)

Primary site	Colon		22 (50.0%)

Rectum		20 (45.5%)

Colorectal		2 (4.5%)

Metastatic sites	Liver		31 (70.5%)

Lung		18 (40.9%)

Lymph nodes		8 (18.2%)

Other (mediastinum, pelvis, perineum)		4 (9.1%)

Peritoneum		2 (4.5%)

Number of target lesions	1		11 (25.0%)

2		12 (27.3%)

3		10 (22.7%)

4 or more		11 (25.0%)

Prior therapy	Surgery		38 (86.4%)

Radiotherapy		11 (25.0%)

Chemotherapy

 Metastatic		44 (100.0%)

Time from initial diagnosis to inclusion, months	Median	17.0

Range	2.8–81.1


Category of intervention	Effective interventions for nurse retention	Strength of evidence*

A. Education and continuous professional development interventions	-Recruitment from, and training in, rural areas	Moderate [26]#

-Targeted admission of students from rural background	Moderate [28]#

-Early and increased exposure to rural practice during undergraduate studies

-Support for continuous professional development

B. Regulatory interventions	-Increased opportunities for recruitment to civil service	Low [25]#

-Recognizing overseas qualifications

-Producing different types of health workers

C. Financial incentives	-Direct and indirect financial incentives (direct payments, service-requiring scholarships, educational loans with service requirements, loan repayment programs)	Moderate [24]#

Low [25]

D. Personal and professional support	-General improvement in rural infrastructure (housing, roads, phones, water supplies, radio communication, etc.)	Strong [25]

-Supportive supervision (mentorship, preceptorship, clinical supervision)	Moderate [26]#

 	-Measures to reduce health workers’ feeling of isolation (professional/specialist networks, telemedicine and telehealth)	Moderate [27]#


Brain region	MR image	PET image

Volume(mm3)	Mean voxel Activity concentrationa (kBq·mL−1)	Mean ROI activity(Bq)	Volume(mm3)	Mean voxelActivity concentrationb (kBq·mL−1)	Mean ROIactivity(Bq)

Left striatum	16.4	0.50	8.19	15.3	0.52	7.95

Right striatum	15.1	0.50	7.56	14.7	0.50	7.30

Hippocampus	26.4	0.50	13.22	26.8	0.50	13.38

Frontal cortex 	46.1	0.50	23.03	48.6	0.50	24.13

Posterior cortex 	49.6	0.50	24.80	48.9	0.49	23.96

Medulla oblongata	15.7	0.50	7.85	15.8	0.49	7.75

Cerebellum	86.7	0.50	43.35	86.0	0.49	42.14


Reaction type	All reactions	Reaction following GAb

 	N	% of all reactionsa	N	% of reaction types, where reaction followed GA

Nausea and/or vomiting	400	27.5%	295	73.8%

Pruritus	243	16.7%	232	95.5%

Constipation	155	10.6%	107	69.0%

Diarrhea (9/88 with vomiting)	88	6.0%	0	0.0%

Somnolence (without cardio-respiratory symptoms)	50	3.4%	34	68.0%

Respiratory depression (41)/arrest (3)	44	3.0%	43	97.7%

Candidiasis	41	2.8%	0	0.0%

Urinary retention	40	2.7%	37	92.5%

Rash	31	2.1%	3	9.7%

Hypokalemia	25	1.7%	0	0.0%

Hypotension	22	1.5%	9	40.9%

Hepatotoxicity(6)/increased transaminases (12)c	18	1.2%	1	5.6%

Stomatitis	16	1.1%	0	0.0%

Myoclonus	15	1.0%	14	93.3%

Pancytopenia	13	<1%	0	0.0%

Hyperglycemia	12	<1%	0	0.0%

Hypertension	11	<1%	2	18.2%

Allergic reactions	10	<1%	3	30.0%

Pain (4/10 pain in jaw, 2/10 back pain)	10	<1%	0	0.0%

Other reactions ( occurred <10 times)	213	14.6%	65	30.5%

Total	1,457	 	845	58.0%


Number of patients	Disease progression	Localized	P Value

Age(Range)	57.19 (36.85-74.92)	60.61 (44.38-91.38)	0.1692

Median Time to Relapse (years)	1.59 (0.23-4.91)

Median Followup (years)	6.47 (4.53-13.84)

Sex

 Male	21	22

 Female	7	15	0.2898

Smoking Status

 Yes	15	15

 No	13	22	0.3256

Tumor Stage11

 T2	6	15	0.1176

 T3	22	22

Fuhrman Grade

 Grade 1-2	7	22

 Grade 3-4	21	15	*0.0066


Matrix	Original (μg/kg)	Spiked (μg/kg)	Determined (μg/kg)	Recovery (%)1

Potato chips	53.2	100	151.2	98.0 ± 0.8

Chips (except potato chips)	<LOQ	100	97.7	97.7 ± 1.0

Biscuits	21.7	100	119.3	97.6 ± 2.7

French fries	35.7	100	135.3	99.5 ± 3.2

Chocolate products	<LOQ	100	96.7	96.7 ± 3.2

Breakfast cereals	9.7	100	117.3	107.6 ± 0.7

Tea products	13.3	100	107.8	94.5 ± 0.2

Seasoned laver	<LOQ	100	102.7	102.7 ± 3.7

Nuts products	<LOQ	100	105.0	105.0 ± 1.6


Subjects	Experimental (non obstructive CAD) group (n)	Control (obstructive CAD) Group (n)	P value*

Females	143	141	0.888

Males	99	101	0.906


	Odds Ratio	[95% Confidence Interval]	p-value

Age group	1.08	1.02 - 1.51	0.02

Family history of renal disease	1.12	0.76 - 1.45	0.05

School education	0.99	0.76 - 2.54	0.17

Physical inactivity	0.65	0.57 - 0.99	0.05

Hypertension	2.15	1.61 - 4.36	0.03

Diabetes	1.22	0.33 - 40.74	0.63

Obesity	1.33	1.05 - 1.98	0.04


Source of variation	df	SSD	VC	% total	P

1. Regions divided by rivers

 Among regions	4	168.349	0.507	23.87	<0.001

 Among populations within regions	44	356.604	1.075	50.60	<0.001

 Within populations	297	161.099	0.542	25.53	<0.001

 Total	345	686.052	2.125

2. Glaciated versus nonglaciated regions during Great Patagonian Glaciation

 Among regions	1	10.703	−0.013	−0.68	n.s.

 Among populations within regions	47	514.250	1.477	73.64	<0.001

 Within populations	297	161.099	0.542	27.04	<0.001

 Total	345	686.052	2.006


Amplified Region	Forward	Reverse

c-KIT exon 8	5'-CAGCAGTCTGACCTATGGC -3'	5'-GCTCAGCTCCTGGACAGAAA-3'

c-KIT exon 9	5'-GATTGATTGATTGATTTTCCTAG-3'	5'-GCAGGCAGAGCCTAAACATC-3'

c-KIT exon 11	5'-CATTTGTTCTCTACCCTAAGTGCT-3'	5'-GTTCCCTAAAGTCATTGTTACACG-3'

c-KIT exon 13	5'-CTGATTAAGTCGGATGCGGC-3'	5'-CAAGCACTGTCGCAATGG-3'

c-KIT exon 17	5'-ATAGCAGCATTCTCGTGTTG-3'	5'-AACTAAAATCCTTCACTGGACTG-3'

PDGFRA exon 12	5'-TTAATGGCTCTGATTGCTCAC-3'	5'-CACCCAGTGCTCATAACCTC-3'

PDGFRA exon 14	5'-ACTGGTTTTGGTTCCCACAG -3'	5'-CAATGATTCGCAGCAACG-3'

PDGFRA exon 18	5'-TAGCTCAGCCGTGGGTATG-3'	5'-CACATGAGCAGAGATGTCAGG-3'


Year range	No. records	Mortality (%)	Countries

An. arabiensis

Up to 2000 (first year = 1996)	3	Min 100	South Africa

Max 100

Mean 100

2001–2005	67	Min 75	Cameroon, Kenya, Madagascar, Mozambique, Nigeria, South Africa, Sudan, Tanzania

Max 100

Mean 95.6

2006–2010	218	Min 0	Burkina Faso, Cameroon, Chad, Ethiopia, Kenya, Mozambique, Senegal, Sudan, Tanzania, The Gambia, Uganda, Zambia, Zimbabwe

Max 100

Mean 79.3

2011–2015	161	Min 9	Ethiopia, Kenya, Malawi, Mali, South Africa, Senegal, Sudan, Tanzania, Uganda

Max 100

Mean 74.7

An. coluzzii

2001–2005	38	Min 19	Benin, Cameroon, Nigeria

Max 100

Mean 89.7

2006–2010	144	Min 0.9	Benin, Burkina Faso, Cameroon, Côte d’Ivoire, Ghana, Mali, Nigeria

Max 100

Mean 73.2

2011–2015	44	Min 1	Benin, Burkina Faso, Cameroon, Côte d’Ivoire, Mali, Mozambique, Liberia

Max 100

Mean 60.6

An. gambiae

Up to 2000 (first year = 1999)	10	Min 100	Zambia

Max 100

Mean 100

2001–2005	55	Min 27	Angola, Burundi, Cameroon, Equatorial Guinea, Mozambique, Nigeria, Uganda

Max 100

Mean 88.82

2006–2010	139	Min 0	Benin, Burkina Faso, Burundi, Cameroon, Congo, Ghana, Guinea, Kenya, Malawi, Mozambique, Uganda, Zambia

Max 100

Mean 75.2

2011–2015	48	Min 0	Cameroon, DRC, Ghana, Kenya, Mali, Tanzania, Uganda

Max 100

Mean 48.7

An. melas

All years (2005)	4	Min 100	Cameroon

Max 100

Mean 100

An. quadriannulatus

All years (2002)	1	Min 100	South Africa

Max 100

Mean 100


Primary antibodies	Secondary antibodies

Antibody	Company	Tissue	Dilution	Antibody	Company	Tissue	Dilution

Brn-3a	Santa Cruz	Retina	1:100	Donkey anti-goat Alexa Fluor 488	Dianova	Retina	1:1000

C1q	Quidel	Retina	1:2500	Donkey anti-goat IgG Cy3	Abcam	Retina	1:750

C3	Cedarlane	Retina	1:500	Goat anti-rabbit IgG Cy 3	Linaris	Retina	1:500

		Optic nerve	1:500			Optic nerve	1:500

C5b-9 (MAC)	Biozol	Retina	1:100	Donkey anti-mouse Dy Light 488	Dianova	Retina	1:250

		Optic nerve	1:100	Goat anti-mouse Alexa Flour 488	Invitrogen	Optic nerve	1:500

MASP2	Biozol	Retina	1:400	Donkey anti-rabbit Alexa Fluor 555	Invitrogen	Retina	1:400

		Optic nerve	1:100			Optic nerve	1:700

MBP	Millipore	Optic nerve	1:100	Goat anti-mouse Alexa Flour 488	Invitrogen	Optic nerve	1:500


 	 	Baseline	Two sessions	After pre-treatment	Start pain rehab treatment	Finish pain rehab treatment	6 months after T3

 	Abbr.	T0a	 	T1	T2a	T3a	T4

Covariates

Demographics patient	 	x

Primary outcome effect evaluation

Participation	USER-P	x	 	x	 	x	x

Secondary outcomes effect evaluation

Physical functioning/disability	PDI	x	 	 	x	x	x

Pain intensity	VAS	x	 	 	x	x	x

Main complaints	PSC	x	 	 	x	x	x

Drop-out/adherence	 	 	 	#	 	#

Self-efficacy/perceived competence	GSE	x	 	x	 	x	x

Pain-specific self-efficacy scale	CPSS_V2	x	 	x	 	x	x

Cost-effectiveness evaluation

Cost questionnaire	Tic-P	x	 	 	x	 	x

Productivity losses	SF-HLQ	x	 	 	x	 	x

Quality of life/health status	SF-36	x	 	 	x	x	x

Potential active ingredients MI

Stages of change	MPRCQ 2	x	 	x

MI integrity/fidelity	 	 	*

Potential moderators

Credibility and expectancy of the treatment	CEQ	x	 	x	x

Motivation	TMQ	x	 	x

Depression	BDI	x	 	 	x	x

Acceptance	AAQ-II	x	 	x	 	x

Flexible goal-adjustment	FGA	x	 	x	 	x

Process evaluation

Satisfaction with (pre-)treatment	 	 	 	x +

Client-centeredness	CCCQ	 	 	x

Feasibility	 	 	 	+


Method	Total number	Disorder number	Success rate

Subcutaneous injection of sesame oil	10	0	0.00%

Subcutaneous injection of DHEA	40	25	62.50%


PBMS	Comparison of PBMS parameters between study groups

Domains	control	intervention	range	p

 	Sub-domains

1 Attitude	3.5 (1.9)	3.0 (1.8)	0-9	.04*

 	a: expectations regarding outcomes	1.8 (0.6)	1.6 (0.6)	0-3	.001*

 	b: values of expected outcomes	1.8 (0.6)	1.8 (0.6)	0-3	.55

2 Social norm	2.1 (1.2)	1.7 (1.0)	0-9	.006*

 	a: assumed attitudes of important others	1.9 (0.6)	1.8 (0.7)	0-3	.28

 	b: motivation to comply with these norms	1.1 (0.4)	1.0 (0.4)	0-3	.004*

3 Control beliefs	3.2 (2.1)	2.9 (2.1)	0-9	.313

 	a: assumed facilitators or barriers	1.6 (0.7)	1.4 (0.8)	0-3	.14

 	b: perceived power of these factors	1.8 (0.6)	1.7 (0.7)	0-3	.42

Intention estimate	8.9 (4.1)	7.5 (4.4)	0-27	.04*


Groups	UACR (mg/g)	Total

Normal albuminuria (NA) (n = 35)	UACR < 30	n = 80

Microalbuminuria (MA) (n = 30)	30 ≤ UACR < 300

Clinical albuminuria (CA) (n = 15)	UACR ≥ 300

Normal group (NC) (n = 80)	Non-diabetic subjects	n = 80


	All patients	CN-AML patients

Final model	HR	95% CI	P-value	HR	95% CI	P-value

Presence of unfavorable karyotype	2.54	1.56–4.12	<0.001	NA	NA	NA

Presence of SNP-A lesion(s)	2.25	1.39–3.65	0.001	2.38	1.28–4.43	0.006

Presence of NPM1 mutation	1.12	0.67–1.87	0.68	NA	NA	NA

Presence of EVI1 overexpression	1.63	0.87–3.06	0.12	NA	NA	NA

Presence of DNMT3A mutation	NA	NA	NA	1.91	1.02–3.56	0.042

Presence of IDH2R140 mutation	NA	NA	NA	0.38	0.09–1.63	0.19

Randomization in the GO arm	0.75	0.49–1.13	0.17	0.51	0.27–0.98	0.043


Closest taxon 	Log inactivation	Resistance (log10(CFU·100 mL−1))

Maximum	Treatment	Minimum 	Treatment

A. hydrophila	0.84	10.43	TI 30 mg·L−g/15 min	11.27	TII 20 mg·L−g/0 min

E. coli	1.31	10.15	TI 8 mg·L−g/30 min	11.45	TIII 8 mg·L−g/30 min

E. coli PD3	1.86	10.62	TIII 30 mg·L−g/0 min	12.48	TI 30 mg·L−g/0 min

E. coli BL21	0.80	10.37	TI 8 mg·L−g/0 min	11.18	TII 20 mg·L−g/0 min

E. cloacae	0.81	10.38	TIII 30 mg·L−g/30 min	11.19	TIII 8 mg·L−g/0 min


Phylogenetic Group	A	B

A1	A2	A3

Predicted CDS	EhV-84	EhV-86	EhV-88	EhV-145	EhV-164	EhV-201	EhV-203	EhV-207	EhV-208	EhV-99B1	EhV-202	EhV-18	EhV-156

hypothetical protein	27	3	4	7	8	4	4	9	9	6	18	9	6

putative endonuclease										2

putative membrane protein		2		1	1					4

putative transposase										1

putative DUF814 domain containing protein										1

zinc finger protein							1

putative ribonuclease												1	1

glycosyltransferase family 29 (sialyltransferase)												1	1

Total	27	5	4	8	9	4	5	9	9	15	18	11	8


	Exposure time [min]	HIV-1 titer [TCID50/ml] after exposure to uncoated and coated coverslip and after washing with 0.49 ml of PBS	HIV-1 titer reductiona	p-valueb

Coverslip #1	Coverslip #2	Coverslip #3

Uncoated coverslip	5	3981	3981	3981	-	-

20	3981	1000	3981	-	-

Coated coverslip by heat polymerization	5	251	1259	1000	79 %	<0.001

20	316	251	316	90 %	<0.05

Coated coverslip by photopolymerization	5	63	63	63	98 %	<0.001

20	0	20	0	99.8 %	<0.05


Gender	Functional dyspepsia	Organic dyspepsia	Total

Male	72 	40	112

Female	120	64	184

Total	192	104	296


Names	Sequence (5′–3′)	Tm (°C)	Mw

Osa-miR156	UGA CAG AAG AGA GUG AGC AC	57.3	6279

(Biotin)-miD156rk	(Biotin)-A CGT GCT CAC TCT CTT CTG TCA	60.5	6587+

(DIG)-miD156rk	(DIG)-A CGT GCT CAC TCT CTT CTG TCA	60.5	6587+

miD156	TGA CAG AAG AGA GTG AGC AC	57.3	6201+

miD156(−1)	TGA gAG AAG AGA GTG AGC AC	55.4	6241

miD156(−3)	aGA CAG gAG gGA GTG AGC AC	57.4	6242

miD156(−5)	aGA CAG gAG tGA GTc AGC gC	59.5	6193+

let-7a	UGA GGU AGU AGG UUG UAU AGU U	46.1	7244

(Biotin)-let-7rk	(Biotin)-ACA ACT ATA CAA CCT ACT ACC TCA	52.6	7166+

(DIG)-let-7rk	(DIG)-ACA ACT ATA CAA CCT ACT ACC TCA	52.6	7166+


Test microorganisms	Inhibition zone diameter (mm) ¥	MIC (μg/ml)	MIC of penicillin (μg/ml)

Bacillus subtilis MTCC 736	25 ± 1.0	2.0	0.5

Bacillus circulans MTCC 8074	23 ± 1.2	3.0	0.5

Bacillus megaterium MTCC 8075	26 ± 1.5	2.0	0.5

Staphylococcus aureus MTCC 96	31 ± 0.9	0.5	0.25

Staphylococcus aureus (Clinical isolate)	30 ± 0.9	0.5	0.25

Micrococcus luteus MTCC 2987	25 ± 1.3	2.0	0.5

Mycobacterium phlei MTCC 1724	25 ± 1.0	2.0	0.5

Mycobacterium smegmatis MTCC 6	21 ± 0.5	3.0	1.0

Escherichia coli MTCC 739		ND	ND

Klebsiela pneumoniae MTCC 3040		ND	ND

Pseudomonas aeruginosa MTCC 2453		ND	ND


Parameter	All subjects%	M%	F%	P

Living with one’s family	63.1	78.6	51.5	<0.001**

Regular exercise	61.7	84.1	44.5	<0.001**

Smokes cigarettes	19.7	13.6	24.2	0.023

Consumed alcoholic beverages	36.1	39.3	33.7	NS

Experienced drugs	16.4	17.0	15.9	0.01*


	SOD (% of Control)	Catalase (% of Control)	Glutathione Reductase (% of Control)	Glucose-6-phosphate Dehydrogenase (% of Control)

BDP 2 μg	135 ± 2	136 ± 3	134 ± 3	132 ± 3

BDP 5 μg	105 ± 3	102 ± 4	103 ± 3	127 ± 4

BDP 10 μg	192 ± 5	204 ± 7	183 ± 2	237 ± 2


Use diversity	D. sisso	A. modesta	A. nilotica	C. desidua	M. boxifolia	Z. nummularia	M. nigra	M. azidarach	W. coagulans	R. stricta	Total	Rank

Construction	5	2	3	1	2	3	4	3	1	1	25	2

Agriculture	4	2	2	3	2	2	2	1	1	1	20	5

Firewood	3	4	3	2	3	2	3	2	2	2	26	1

Fodder	2	3	3	2	2	3	3	2	3	1	24	3

Medicinal	1	3	3	3	2	2	1	2	3	3	23	4

Total	15	14	14	11	11	12	13	10	10	8

Rank	1	2	2	5	5	4	3	6	6	7

Market price in US$/Kg	0.6	0.5	0.5	0.2	0.53	0.4	0.4	0.2	0.9	0.8


Group	n	Expression of ELF

High	Low

Normal liver tissues	20	20(100.0%)	0(0.0%)

Adjacent tissues*	84	65(77.4%)	19(22.6%)

HCC tissues*#	84	40(47.6%)	44(52.4%)


Externality category	UK	USA	Germany

€ million	€ per kg a.i.	€ million	€ per kg a.i.	€ million	€ per kg a.i.

Pesticides in drinking water	217	9.06	851	2.00	137	5.15

Pollution incidents, fish deaths and monitoring costs	15	0.68	122	0.29	39	1.47

Biodiversity and wildlife losses	23	1.01	157	0.37	5	0.18

Cultural, landscape and tourism	90	3.98	nd	nd	nd	nd

Bee colony losses	2	0.08	109	0.26	2	0.04

Acute effects of pesticides on human health	2	0.08	127	0.30	21	0.80

Totals	349	15.5	1366	3.2	202	7.6


	ABTS (μmol/mL)	DPPH (μmol/mL)	FRAP (mmol/mL)

Raw hydrolysate supernatant	5.34 ± 1.29	0.18 ± 0.08	0.60 ± 0.04

After ultrasound treatment	5.92 ± 0.96	0.27 ± 0.07	0.73 ± 0.04

After autoclaving	7.03 ± 1.34	0.24 ± 0.05	0.79 ± 0.05


ADAPT-ITT phase	Methodology

1. Assessment	Conducted focus groups/needs assessment with Community Advisory Board (CAB)

2. Decision	Decision regarding type of intervention was pre-determined by evidence base; however, decisions regarding characteristics of the intervention (equipment and study structure) were made.

3. Administration	Theater testing was conducted during the CAB focus groups with patient stakeholders prior to intervention implementation.

4. Production	A draft of the tailored intervention was presented to the CAB for further feedback and approval.

5. Topical experts	The study team specifically recruited topical experts for CAB membership; see Table 2.

6. Integration	CAB input was integrated into the final adapted version of the intervention; the telehealth software company revised the software to reflect CAB recommendations.

7. Training	Both clinical and installation experts received training with regard to study structure and equipment use.

8. Testing	A pilot test of the intervention was conducted with 10 patients to identify “hands-on” challenges requiring adaptation; a focus group was then held with 4 of those patients to further explore these challenges and solutions


No.	Species	GenBank accession No.	Locality	Voucher ID

1	Cyrtodactylus badenensis	KF929505	Vietnam, Tay Ninh Prov.	KIZ13689

2	C. bansocensis	KU175573	Laos, Khammouane Prov.	VNUF–R.2015.20

3	C. bansocensis	KU175574	Laos, Khammouane Prov.	NUOL-R-2015.21

4	C. bobrovi	KT004368	Vietnam, Hoa Binh Prov.	IEBR-A.2015.30

5	C. bobrovi	KT004369	Vietnam, Hoa Binh Prov.	VNMN-A.2015.61

6	C. calamei	KX064043	Laos, Khammouane Prov.	NUOL-R-2015.22

7	C. calamei	KX064044	Laos, Khammouane Prov.	VNUF-R.2015.28

8	C. cryptus	KF169971	Vietnam, Quang Binh Prov.	PNKB3

9	C. cryptus	KF169972	Vietnam, Quang Binh Prov.	PNKB4

10	C. cryptus	KX064038	Laos, Khammouane Prov.	VNUF-R.2014.69

11	C. elok	HM888478	Malaysia	ZMMU-RAN1991

12	C. darevskii	HQ967221	Laos, Khammouane Prov.	ZISP-FN256

13	C. darevskii	HQ967223	Laos, Khammouane Prov.	ZISP-FN223

14	C. hinnamnoensis	KX064045	Laos, Khammouane Prov.	IEBR-A.2013.89

15	C. hinnamnoensis	KX064046	Laos, Khammouane Prov.	IEBR-A.2013.90

16	C. hinnamnoensis	KX064047	Laos, Khammouane Prov.	VNUF-R.2015.11

17	C. hinnamnoensis	KX064048	Laos, Khammouane Prov.	VNUF-R.2015.3

18	C. hinnamnoensis	KX064049	Laos, Khammouane Prov.	NUOL-R-2015.9

19	C. lomyenensis	KJ817436	Laos, Khammouane Prov.	IEBR-KM2012.54

20	C. lomyenensis	KP199942	Laos, Khammouane Prov.	IEBR-KM2012.52

21	C. interdigitalis	KX077901	Laos, Khammouane Prov.	VNUF-R.2014.50

22	C. jaegeri	KT004364	Laos, Khammouane Prov.	IEBR-A.2013.55

23	C. jaegeri	KT004365	Laos, Khammouane Prov.	NUOL-R.2013.1

24	C. jaegeri	KT004366	Laos, Khammouane Prov.	VFU-TK914

25	C.cf. jarujini	KX077907	Laos, Bolikhamxay Prov.	VNUF-R.2015.7

26	C. khammouanensis	HM888467	Laos, Khammouane Prov.	ZISP-FN191

27	C. khammouanensis	HM888469	Laos, Khammouane Prov.	ZISP-FN257

28	C. kingsadai	KF188432	Vietnam, Phu Yen Prov.	IEBR-A.2013.3

29	C.cf. martini	KF929537	China, Yunnan Prov.	KIZ201103

30	C. multiporus	HM888472	Laos, Khammouane Prov.	ZISP-FN3

31	C. multiporus	HM888471	Laos, Khammouane Prov.	ZISP-FN2

32	C. otai	KT004370	Vietnam, Hoa Binh Prov.	IEBR-A.2015.26

33	C. otai	KT004371	Vietnam, Hoa Binh Prov.	IEBR-A.2015.27

34	C. puhuensis	KF929529	Vietnam, Thanh Hoa Prov.	KIZ11665

35	C.aff. pulchellus	HQ967202	Malaysia	ZMMU-R-12643-3

36	C.aff. pulchellus	HQ967203	Malaysia	ZMMU-R-12643-4

37	C. pageli	KJ817431	Laos, Vientiane Prov.	ZFMK91827

38	C. pageli	KX077902	Laos, Vientiane Prov.	NQT2010.36

39	C. pageli	KX077903	Laos, Vientiane Prov.	NQT2010.37

40	C. phongnhakebangensis	KF929526	Vietnam, Quang Binh Prov.	PNKB2011.30

41	C. phongnhakebangensis	KF929527	Vietnam, Quang Binh Prov.	PNKB2011.32

42	C. pseudoquadrivirgatus	KF169963	Vietnam, Thua Thien - Hue Prov.	ITBCZ3001

43	Cyrtodactylussp. 1	KP199949	Vietnam, Da Nang, Ba Na	ZMMU-R-13095-2

44	C. quadrivirgatus	HM888465	Malaysia	ZMMU-RAN1989

45	C. quadrivirgatus	HM888466	Malaysia	ZMMU-RAN1990

46	C. roesleri	KF929532	Vietnam, Quang Binh Prov.	PNKB2011.34

47	C. roesleri	KF929531	Vietnam, Quang Binh Prov.	PNKB2011.3

48	C. rufford	KU175572	Laos, Khammouane Prov.	VFU-R.2015.14

49	C. sommerladi	KX064039	Laos, Khammouane Prov.	IEBR-A.2015.37

50	C. sommerladi	KX064040	Laos, Khammouane Prov.	VNUF-R.2013.22

51	C. sommerladi	KX064041	Laos, Khammouane Prov.	VNUF-R.2013.87

52	C. sommerladi	KX064042	Laos, Khammouane Prov.	IEBR-A.2015.39

53	C. spelaeus	KP199947	Laos, Vientiane Prov.	ZMMU-R-13980-3

54	C. spelaeus	KP199948	Laos, Vientiane Prov.	ZMMU-R-13980-1

55	C. soudthichaki	KX077904	Laos, Khammouane Prov.	NUOL-R-2015.5

56	C. soudthichaki	KX077905	Laos, Khammouane Prov.	VFU-R.2015.18

57	C. soudthichaki	KX077906	Laos, Khammouane Prov.	IEBR-A.2015.34

58	C. teyniei	KJ817430	Laos, Khammouane Prov.	IEBR-KM2012.77

59	C. teyniei	KP199945	Laos, Khammouane Prov.	IEBR-KM2012.77

60	C. vilaphongi	KJ817434	Laos, Luang Prabang Prov.	NUOL-R-2013.5

61	C. vilaphongi	KJ817435	Laos, Luang Prabang Prov.	IEBR-A.2013.103

62	C. wayakonei	KJ817438	Laos, Luang Nam Tha Prov.	ZFMK91016

63	C. wayakonei	KP199950	Laos, Luang Nam Tha Prov.	ZMMU-R-13981-1

64	Cyrtodactylus thathomensissp. nov.	MG791873	Laos, Xiangkhouang Prov.	ZMMU-R-14919-1

65	Cyrtodactylus thathomensissp. nov.	MG791874	Laos, Xiangkhouang Prov.	ZISP 29731

66	Cyrtodactylus thathomensissp. nov.	MG791875	Laos, Xiangkhouang Prov.	ZMMU R-15384


Clinicopathologic Characteristics

Age at diagnosis (years)

 Median (range)	62 (30–80)

Histology (n (%))

 Ductal	44 (90%)

 Lobular	5 (10%)

Histologycal grade (n (%))

 I and II	39 (80%)

 III	10 (20%)

UICC stage (n (%))

 IIB	6 (12%)

 IIIA + IIIB	11 (22%)

 IV	32 (65%)

ER status (n (%))

 positive	49 (100%)

 negative	0 (0%)

PR status(n (%))

 positive	33 (67%)

 negative	16 (33%)

HER2 status (n(%))

 positive	8 (16%)

 negative	41 (84%)


Univariate Analysis of log(MIF) over Time

	Den DF	F Value 	P-Value	Slope Estimator	SD (Estimator)

Continuous variable

Age	47.7	0.03	0.8604	−0.00239	0.01351

BMI	47.8	0.34	0.5605	−0.02082	0.03551

Baseline MIF, logarithmized	42.2	11.44	0.0016 *	0.4456	0.1317

Categorical variable

Gender (male)	48	0.07	0.7942	−0.0857	0.3267

Endovascular repair	48.2	0.01	0.9172	−0.02937	0.2809

Continuous variable (repeated measurements)

Serum creatinine	171	3.11	0.0796	0.2094	0.1187

Apache II	137	12.92	0.0005 *	0.04273	0.01189


	Men/Boys	Women/Girls

Caritas population	Barcelona residents	Caritas population	Barcelona residents

Direct Assistance Services	Housing Mediation Service	Overall	Deprived social classes (IV and V)	Direct Assistance Services	Housing Mediation Service	Overall	Deprived social classes (IV and V)

Adults

 Regular or poor self-reported health	24.4	45.8	11.2	12.8	53.1	60.3	15.3	20.5

 Quality of life, below the median score in Cáritas	35.6	51.4	5.6	4.4	47.7	58.9	8.3	13.1

 Poor mental health (Goldberg-12)	62.2	75.0	11.5	12.1	66.9	72.6	15.2	17.4

 Self-reported depression or anxiety the previous year	57.8	70.8	5.8	6.8	63.8	86.1	9.2	10.6

 Consumption of tranquilizers, antidepressants, or sleeping pills the previous 2 days	6.7	18.1	6.7	8.3	15.4	30.1	15.7	13.8

 Self-reported migraine or frequent headaches during the previous year	28.9	38.9	3.6	3.6	62.3	65.8	8.5	7.9

 Self-reported backache during the previous year	37.8	63.4	12.0	15.8	73.9	83.6	19.2	18.9

 6 or less daily mean hours of sleep (working days)	45.5	56.9	22.1	22.1	53.1	61.1	24.9	30.6

Children

 Regular or poor health status	22.7	7.1	0.9	NE	22.9	22.0	1.7	NE

 Poor mental health (SDQ questionnaire)	61.3	45.2	3.1	NE	37.5	25.0	5.1	NE

 Recurrent otitis during the previous year	20.5	19.0	3.6	NE	31.9	19.5	1.6	NE

 Not having had breakfast everyday before leaving home	15.9	26.2	6.4	15.4	20.8	22.0	8.4	14.5


GENE	Sense	Anti-sense	Product

ABCA1	5’-AGGCCCAGACCTGTAAATGC-3’	5’-CTCACCAACCTTGCCAACTTC-3’	450 bp

SREBP2	5’-CAGACGCCAAGATGCACAAG-3’	5’-TGGCTCATCTTTGACCTTTGC-3’	323 bp

CYP7A1	5’-CATTTGGGCACAGAAGCATTG-3’	5’-AGGCAGCGGTCTTTGAGTTAG-3’	174 bp

NR1H3 (LXR α)	5’-AAGAAACTGAAGCGGCAAGA-3’	5’-AGCAATGAGCAAGGCAAACT-3’	555 bp

PRKAA2 (AMPK α2)	5’-TCAATCGTTCTGTCGCCAC-3’	5’-ATACGGTTTGCTCTGACTTCG-3’	530 bp

HMGCR	5’-CTCCGCAGGCTATTTGTTCAG-3’	5’-GCTAAGAGCGTTCGTGGGTC-3’	620 bp

GAPDH	5’-ACTCCTCCACCTTTGACGCTG-3’	5’-CTCTCTTCCTCTTGTGCTCTTGC-3’	182 bp


District	Percentage (%) scores of:

Total points	Reports	Management of supplies	Information management	Meetings	Technical support	Referrals

Nadowli	58.9	77.4	71.7	69.7	33.6	42.5	58.6

Wa Municipal	73.3	90.3	87.5	88.5	51.0	61.1	61.6

Wa East	54.1	74.5	78.9	74.8	39.2	0.0	57.2

Wa West	60.1	64.1	66.8	74.0	43.1	0.0	52.6

Lawra	30.0	46.6	30.6	28.8	26.0	12.9	35.2


Parameter	Estimate	Std. error	p-Value

Intercept	−3.96	2.90	0.18

Stimulation	1.46	0.74	0.05

Time	0.39	0.10	<0.01

Quadrant	3.27	0.74	<0.01

Sequence	5.99	0.98	<0.01

Time × sequence	−0.18	0.07	0.01

Variance components		SD

Subjects		6.72


Manufacturer	Name of Product	Vaccine Type	Adjuvant	Produced in	Age Recommended

Abbot healthcare	Trivalent: Influvac Imuvac	Inactivated	None	Egg	From 6 months

AstraZeneca	Quadrivalent: Fluenz Tetra (Flumist quadrivalent) Trivalent: Fluarix Alpharix Influsplit	Live attenuated	None	Egg	From 24 months to 17 years Trivalent: From 6 months

GlaxoSmithKline	Quadrivalent: Fluarix Tetra Alpharix Tetra Influsplit Tetra	Inactivated/split	None	Egg	From 3 years

Novartis	Trivalent: Agrippal Fluvirin Fluad	Inactivated/subunit	None None Squalene (MF59)	Egg	From 6 years From 4 years From 65 years

Pfizer/CSl Australia	Trivalent: Afluria Enzira	Inactivated	None	Egg	From 5 years

Sanofi Pasteur	Trivalent: Vaxigrip Intanza 9 μg Intanza 15μg	Inactivated	None	Egg	From 6 months From 18-59 years From 60 years


Study	Measure	Assessed variable	Time of assessment

Study 1 cultural validity	Cultural Relevance Questionnaire (CRQ)	Culturally adapted internet-delivered treatment	Completed by experts and users before the trial.

Study 2 efficacy trial	Patient Health Questionnaire (PHQ-9)	Depression symptoms	Baseline, post-treatment and follow- up

Generalised Anxiety Disorder 7 (GAD-7).	Anxiety symptoms	Baseline, post-treatment and follow- up

Sociodemographic & Clinical History Questionnaire	Gender, age, marital status, education, occupation, socioeconomic status and clinical history	Baseline

Helpful and Hindering Aspects of Treatment (HAT)	Helpful and hindering aspects of treatment	After each session

Satisfaction with Treatment (SAT)	Satisfaction with therapy	Post-treatment


Author, date	Conclusions	Contributions

Levy et al., 2009 [1]	AUT is not a monogenic disorder, in many individuals may be the result of a complex amalgam of multiple simultaneous genetic variations, and present morphological and functional brain abnormalities.	Highlights the importance of understanding biological markers, patterns of cortical organization and connectivity in advancing the treatment of AUT.

Baron-Cohen et al., 2000 [19]	Unlike those with TD in ToM tests, patients with AS or AUT do not show activation of the amygdala when making mentalistic inferences from the eyes. The amygdala may be one of many abnormal neural regions in AUT.	Highlights the role of the amygdala in the symptoms of ASD.

Castelli et al., 2002 [20]	The physiological cause for the mentalizing dysfunction in AUT can be a bottleneck in the interaction between perceptual processes of higher and lower order.	Relates the difficulties in understanding socially relevant movements in AUT to information processing in the visual cortex.

Brunet et al., 2000 [21]	Attribution of intentions to others is associated with a complex brain activity involving the right medial prefrontal cortex when a nonverbal task is used.	Presents data that validate hypothesis of abnormal brain activation in patients with impaired mentalizing.

Castelli et al., 2000 [22]	The regions responsible for processing information about intentions and the ability to make inferences about the mental states of others may have evolved from the ability to make inferences about the actions of other creatures.	Suggests evolutionary history for the abilities that make ToM.

Pierce et al., 2001 [23]	Compared to typical individuals, autistic "see" faces using different neural systems, unique to each individual.	Experiential factors play an important role in the development of the fusiform facial area, related to the processing faces.

Scholz et al., 2009 [24]	There are neighboring but distinct regions in the right temporo-parietal junction involved in ToM and orientation of attention.	Identifies difficulties in the investigation of brain functions that occupy regions close to each other or overlapping.

Johnson et al., 2007 [25]	There is involvement of frontal and parietal attentional networks and sub-cortical excitatory systems in ADHD and a prefrontal cortex dysfunction in children with HFA.	Provides detailed evidence of dysfunction in sustained attention in ADHD significantly higher than in HFA.

Kana et al., 2007 [26]	The neural circuit linked to inhibition in individuals with ASD is atypically activated and is less synchronized, leaving inhibition to be accomplished by strategic control rather than automatically.	Identifies dysfunction in inhibitory cortical level, being disorganized and desynchronized.

Schultz et al., 2000 [27]	Individuals with ASD demonstrate during facial discrimination, a pattern of brain activity consistent with strategies based on characteristics or traits more typical of the perception of non-facial objects.	Highlights possible dysfunction in processing stimuli related to biological and inanimate objects in ASD.

Dapretto et al., 2006 [28]	A dysfunctional mirror neuron system may underlie the social deficits of autism.	Substantiates hypothesis of the importance of mirror neurons in the development of social functions.

Jones et al., 2008 [29]	The behavior of eye contact is already noticeably compromised in children two years of age with ASD, accompanying the person with autism for life.	Subsidizes and highlights the importance of early diagnosis of ASD.


Data collection	Measurement tool	Data collected method	Timeframe

Measurement of total ulcer area	Centimetres squared;	Research assistant	Weekly: Post-treatment until healed or at 6 months

Tracing from photographs and counting squares

Measurement of ulcer depth	Centimetres;	Treating podiatrist	Weekly: post-treatment until healed or at 6 months

Using sterile probe

Ulcer pain	Visual analogue pain scale 100 mm	Treating podiatrist	Weekly: Pre-treatment, during treatment, post-treatment until healed or 6 months

Quality of life	EQ-5D-5 L tool	Participant questionnaire	Initial treatment, at 3 months, at 6 months

Direct health costs

Consumable costs for treatments	In dollars for each treatment	Treating podiatrist	Weekly, per participant until healed or at 6 months

Medicare Benefit Scheme (MBS)	MBS Care database, in dollars	Extraction from MBS database	End of project for each participant from initial to final treatment

Pharmaceutical Benefit Scheme (PBS)	PBS Care database, in dollars	Extraction from PBS database	End of project for each participant from initial to final treatment

Inpatient data	Monash Health:	Hospitalisation costs	Monash Health:

Admission duration, reason for admission, imaging and interventions, obtained from the patient record and from the Victorian Admitted Episodes Database	End of project

External organisation: End of project

External organisation: Admission duration, reason for admission, costs of any surgery for diabetes-related foot ulcers will be estimated using WEISS funding

Hospital based services (outpatient data)	Hours – time spent	Treating podiatrist	Weekly per participant until healed or at 6 months

Medical imaging and pathology for outpatients	Dollars – hospital based costs	Treating podiatrist	Monthly per participant until healed or at 6 months

Community based services	Number and cost of appointments	Participant interview	Monthly until healed or at 6 months

Private health appointments	Number and cost of appointments, eligibility for private health subsidies	Participant interview	Monthly until healed or at 6 months

Royal District Nursing Service for ulcer management	Frequency and cost of service	Participant interview	Monthly until healed or at 6 months

Ongoing ulcer care products	Valued using market prices	Participant interview	Monthly until healed or at 6 months

Parking costs for appointments	Dollars	Participant interview	Monthly until healed or at 6 months

Transportation costs to travel to appointments	Estimated through Australian Tax Office car rate cents per km	Participant interview	Monthly until healed or at 6 months

Productivity costs

Time taken from work for participant and/or any family member	Salary and hours taken from work	Participant/family interview	Monthly until healed or at 6 months


Explanatory variable	d.f.	Mean square	F-value	P

TREATMENT	2	0.4168	5.08	0.0302

LARVAE	1	0.2237	3.44	0.0670

TREATMENT (DAY)	9	0.0831	1.28	0.2603

Error	92	0.0651


Variable (units)	Men	Women	P value

N	141	16	-

Age (y)	41.9 ± 9.7	42.0 ± 6.1	0.98

Body mass (kg)	75.0 ± 9.2	56.6 ± 7.1	<0.01

Body surface area (m2)	1.9 ± 0.1	1.6 ± 0.1	<0.01

Height (m)	176 ± 7	161 ± 5	<0.01

Body mass index (kg · m−2)	24.1 ± 2.2	20.9 ± 1.2	<0.01

Best race time (min)	217 ± 34	240 ± 32	0.03

Running experience (yr)	10.7 ± 9.8	9.5 ± 5.9	0.67

Completed marathons (number)	7 ± 3	5 ± 2	0.42

Average training distance · week−1 (km)	62.7 ± 27.8	59.5 ± 26.6	0.69

Training sessions of running · week−1 (number)	4.3 ± 1.0	4.4 ± 1.0	0.68


Murine models of infection	Immune outcome	Reference

FrCasE virus (MLV)	Enhanced memory cellular CD8+ responses	43

Influenza	Prolonged Ag presentation by DC; enhanced proliferation of CD8+ T cells	64

RSV	Modification of CD4+/CD8+ T-cell balance	65

LCMV	Innate immune activation;induction of virus-specific CD8+ T-cell response	66


Sample	Residual level, mg/kg	μg/product

2,6-TDI	IPDI-1	IPDI-2	2,4-TDI	PI	CHI	4,4′-MDI	H12MDI	Total	Total

Glove 1	0.013	ND	ND	ND	ND	ND	0.064	ND	0.077	0.40

Glove 2	ND	ND	0.011	ND	ND	ND	3.0	0.022	3.0	18.7

Pastry bag	0.029	ND	ND	0.004	ND	ND	0.014	ND	0.047	7.4

	2,6-TDA	IPDA		2,4-TDA	ANL	CHA	4,4′-MDA	H12MDA	Total	Total

Glove 1	ND	ND		ND	1.0	ND	29	ND	30	106

Glove 2	ND	ND		ND	0.73	0.43	0.92	3.5	5.6	35

Pastry bag	ND	ND		ND	ND	ND	ND	ND	ND	ND


Number of conditions	OR	95% CI	p-value

No chronic health condition	REFERENCE

Arthritis only	1.64	1.13 – 2.38	0.0099

Arthritis and one other condition	2.95	1.82 – 4.80	<.0001

Arthritis and two other conditions	2.80	1.50 – 5.26	0.0013

Arthritis and three or more other conditions	8.68	5.24 – 14.38	<.0001


Parameter	Value

Highest heart rate	119 ± 25 beats/minute

Highest respiratory rate	31.7 ± 8.9 breaths/minute

Mean APACHE II score	19.8 ± 7.8

Mean SAPS II score	40.2 ± 16.1

Mean white cell count	13.2 ± 10.1 × 109/l

Mean haemoglobin	12.4 ± 2.2 g/dl (lowest value: 7.8 g/dl)

Mean platelet count	217 ± 218 × 109/l

Mean [urea]	13.6 ± 7.6 mmol/l

Mean [creatinine]	222 ± 218 μmol/l


	Within-group difference	Between-group difference	Between-group P-value

	Acu-TENS	Placebo-TENS

Heart rate (beat min−1)	−4.50 (0.49)	0.79 (0.21)	−5.29 (0.37)	 .000

SBP (mmHg)	−4.95 (0.89)	0.35 (1.14)	−5.30 (0.85)	 .206

Rate pressure product	−940.9 (123.9)	140.9 (123.6)	−1081.0 (115.2)	 .010


Item	Home care group (n = 69)	Hospital care group (n = 69)	P	Standardized difference

Gender (n, male/female)	35/34	36/33	0.87	0.03

Age (yr, mean ± SD)	70.7 ± 13.9	70.7 ± 10.8	0.99	0.002

Primary site (n)			1.00

Lung	11	13		0.08

Stomach/esophagus	22	23		0.03

Liver/biliary tract/pancreas	17	15		0.07

Large intestine	9	8		0.04

Breast	2	2		0

Others	8	8		0

Performance status (n)			0.99

0	0	0		(incalculable)

1	12	12		0

2	22	20		0.06

3	27	28		0.03

4	8	9		0.04

Use anti-cancer agents (n, used/unused)a	1/68	2/67	1.00	0.10


	Beta coefficient	SE	t	p-value

Occupation	0.558	0.187	2.98	0.003

Length of VMW career	0.007	0.003	2.28	0.023

Reason for becoming VMW	-0.649	0.089	-7.33	<0.001

Knowledge of malaria transmission	0.989	0.136	7.30	<0.001

Knowledge of vector species	0.307	0.151	2.04	0.042

Knowledge of vector breeding places	0.574	0.139	4.13	<0.001


Parameters	Symbol	Value

Duty factor	β	1/2, 4/5, 5/6

Turning radius	Rturning	600 mm, 800 mm, 1000 mm

Straight radius	RStraight	Inf

Running time	T	30 s

The moment of straight to turning	TS-T	10 s

The moment of turning to straight	TT-S	20 s

Gait period	Tperiod	1 s


Variable	Baseline	Three months	P value

ESR (mean ± SD, mm in the first hour)	25.4 ± 22.4	12.8 ± 18.5	0.038

CRP (mean ± SD, mg/L)	17.6 ± 18.4	10.8 ± 15.9	0.058

Prednisone use, n (%)	7 (44)	7 (44)	1.0

Prednisone dose (mean ± SD, mg/day)	2.0 ± 2.5	2.8 ± 5.2	0.24


Article	Method	MCInc/MCIc	Scans	ACC (%)	SEN (%)	SPE (%)	AUC

Cui et al., 2011	Multivariate predictors (MRI, CSF, and NM scores)	87/56	baseline	67.1	96.4	48.3	0.796

Ye et al., 2012	SLR+SS (MRI, genetic, and cognitive measures)	177/142	baseline	–	–	–	0.859

Eskildsen et al., 2013	Patterns of cortical thinning	134/122	6 months	75.8	75.4	76.1	0.809

		134/123	12 months	72.9	75.8	70.2	0.762

Raamana et al., 2015	Thickness network fusion	130/56	baseline	64.0	65.0	64.0	0.680

Proposed	Combination of MRI and thickness network	83/76	baseline	66.0	55.3	75.9	0.735

		83/61	6 months	76.4	65.6	84.3	0.813

		83/63	12 months	74.7	65.1	81.9	0.785

		83/42	18 months	73.9	70.5	77.1	0.773


	kappa

presence of activity periods	0.905*

presence of rhythmical activity	0.786*

	ICC (95% CI)

amount of activity periods	0.967 (0.951–0.978)*

dominant frequency	0.739 (0.624–0.822)*

second prevalent frequency	0.787 (0.672–0.864)*

third prevalent frequency	0.789 (0.672–0.867)*

minimal frequency	0.351 (0.149–0.525)#

maximal frequency	0.831 (0.750–0.887)*

highest value of acceleration peaks	0.841 (0.768–0.893)*


Theory	Favourable impact of coach change on team performance	Slope of the favourable impact over time

Vicious-circle theory	NO

Ritual scapegoating theory	NO

Common-sense theory	YES	=

Current study	YES	> in the short term and= in the long term


Normal versus tumor biomarkers	LN negative versus LN positive biomarkers

SLC39A5, C3orf32, TP73, CD1B, PCDHGA4, PCDHGA11, PCDHGA9, PCDHGA1, PCDHGB1, PCDHGB6, PCDHGA12, PCDHGB3, PCDHGB7, PCDHGA6, PCDHGA8, PCDHGA10, PCDHGA5, PCDHGB4, PCDHGA3, PCDHGA2, PCDHGB2, PCDHGA7, PCDHGB5, C20orf197, SLC16A5, FUT8, SLC15A2, C17orf93, PRAC, OCLN, TMEM144, FGF2, PDX1, CCL1, LILRB5, LCE3D, GPR45, LPO, CGB5	LAT2, TTC13, ARV1, NMT1, DCAKD, GJA1, OR7A17, LOX, KRT19, ZNF655, KRTAP4-4, TAAR5, SEMA3E, HOXD1


Viruses detected	Patients with acute diarrhea (N = 145) (%)

Norovirus GII	59 (40.7)

Norovirus GI	17 (11.7)

Astrovirus	5 (3.5)

Rotavirus	2 (1.4)

Adenovirus 40/41	0 (0.0)

Coinfections	11 (8.0)

Norovirus GI + GII	5 (3.5)

Norovirus GI + Rotavirus A	1 (0.7)

Norovirus GI + Astrovirus	1 (0.7)

Norovirus GII + Astrovirus	4 (2.8)

At least one virus detected	94 (64.8)

No virus detected	51 (35.2)


 	Lab #1 (Sequencing)	Lab #2 (Sequencing)	Lab #3 (Sequencing)	Lab #4 (Primer Extension)	Lab #5 (Real Time PCR)

Specimen Requirements	Preferred sample type*:Slides from FFPE block 1H&E stained slide sections with tumor circled; 4 matching unstained slides,10 microns each.	Preferred sample type: Archival FFPE or frozen surgical biopsies confirmed to contain >50% tumor by a surgical pathologist.1 H&E slide; 5 unstained sections,10 microns each.	Preferred sample type: FFPE tissue 6 unstained sections,10 microns each.	Preferred sample type: Pre-cut slides from FFPE. Send all slides within 5–7 days of cutting. Air dry. Do not oven dry. Store specimen at room temperature (20–23.5°C). 5 unstained sections, 7 microns each	Preferred sample type: FFPE block, unstained slides, or fresh snap frozen biopsy 5 unstained sections, 7 microns each

Genotyping	Method: PCR amplification followed by Direct Sanger sequencing (Big Dye v. 1.1)Detected mutations: KRAS codons 12 and 13	Method: PCR amplification followed by standard bidirectional sequencing on ABI 3100. Detected mutations: KRAS codons 12 and 13	Method: PCR amplification followed by sequencing.Detected mutations: KRAS codons 12,13 and 61	Method: Single nucleotide primer extension with fragment analysis by capillary electrophoresis using a modified SNaPshot assay. Detected mutations: KRAS codons 12 and 13	Methods are propietary: qualitative real time PCR Detected mutations: KRAS codons 12 and 13

Lower Limit of Detection	20% when ≥ 40% tumor cells present	20%	15-20%	10% when ≥ 2% tumor cells present	1-5%


Behavior	HIV positives

Had sex past year	71.3

Had steady partner past year	50.3

Used condoms with steady partner past month

Never	47.7

Seldom	23.9

Often	13.6

Always	14.8

Had sex with casual female partner past year	35.4

Used condoms with casual female partners past month

Never	42.3

Seldom	22.5

Often	13.5

Always	21.6

Sold sex last year	2.7

Purchased sex last year	20.0

Condom use with FSW last month

Never	45.2

Seldom	20.2

Often	6.7

Always	27.9

Gave used needle to other IDU last week	21.1


	CspA	CspZ	ErpPa	ErpCa	ErpAa	p43	BBK32	BGA66	BGA71	CD59-like protein

Synonyms and other designations	CRASP-1	CRASP-2	CRASP-3	CRASP-4	CRASP-5	–	–	–	–	–

BbCRASP-1	BbCRASP-2	BbCRASP-3 BBN38	BbCRASP-4	BbCRASP-5

BBA68	BBH06			ErpI

ZS7.A68				ErpN

FHBP				BBP38

BBL39

OspE

Gene name	cspA	cspZ	erpP	erpC	erpA	ND	bbk32	bga66	bga71	ND

Origin	Bb, Ba, Bs	Bb	Bb	Bb	Bb	Bb	Bb	Bba	Bba	Bb

Confers serum resistance	Yes	Yes	No	No	No	ND	Yes	Yes	Yes	ND

Interaction with complement regulators/components	FH	FH	FHR-1	FHR-1	FHR-1	C4Bp	C1r	C7, C8, C9, TCC	C7, C8, C9, TCC	TCC

FHL-1	FHL-1	FHR-2	FHR-2	FHR-2

C7, C8, C9, TCC		FHR-5		FHR-5

Interaction with plasmin(ogen)	Yes	Yes	Yes	Yes	Yes	ND	ND	ND	ND	ND

Affected complement pathways	AP, TP	AP	–	–	–	CP/LP(?)	CP	TP	TP	TP


	Danish early-vaccination era data set	Global post-vaccination era data set

Length of sequences	800	800

Number of sequences	18	40

Average number of differences	12.2	31.0

# synonymous substitutions	26	131

# non-synonymous substitutions	32	71

Average Pi (nucleotide diversity)

1. all sites	0.014	0.040

2. synonymous sites	0.030	0.109

3. non-synonymous sites	0.009	0.019

Transition/transversion bias	2.2	9.4

Codon usage bias (ENC)	53	55


Characteristics	Number (%)	Characteristics	Number (%)

Kebele	 	Religion

 Yikaho	63(15.1)	Orthodox Christian	337(80.6)

 Mahdid	62(14.8)	Muslims	81(19.4)

 Bambaho	126(30.1)	Educational level

 Dubaba	167(40)	Illiterate	248(59.3)

Gender	 	Primary (grades 1–8)	142(34.0)

 Male	262(62.7)	Secondary and above	28(6.7)

 Female	156(37.3)	Occupation

Age (years)	 	Farmer	349(83.5)

 18-24	67(16.0)	Others	69(16.5)

 25-49	303(72.5)	Family size

 50-64	35(8.4)	1-4	230(55.0)

 65+	13(3.1)	5+	188(45.0)

Ethnicity

 Amhara	293(70.1)

 Agew	63(15.1)

 Gumuz	62(14.8)

Marital status

 Unmarried	48(11.5)

 Married	365(85.2)

 Others	14(3.3)


Protein	Gene	Hz vs WT (fold change)	P value	Hz + IGF-1 vs Hz (fold change)	P value

IGF-1R and Intracellular signaling

 Insulin-like growth factor 1 receptor	igf1r	1.44	0.0001	1.29	0.001

 Neuroblastoma ras oncogene	nras	1.53	0.0004	−1.08	0.001

 Jun oncogene	jun	−2.03	0.0006	1.05	0.01

 FBJ osteosarcoma oncogene	fos	−1.44	0.001	−1.16	0.13

Inflammation and apoptosis

 Chemokine (C-C motif) receptor 5	ccr5	4.38	0.0001	−4.87	0.0001

 Chemokine (C-C motif) ligand 6	ccl6	4.34	0.0002	−4.02	0.0001

 Colony stimulating factor 1 receptor	csf1r	2.49	0.0004	−2.41	0.0006

 Complement component 1, q subcomponent, α p	c1qa	5.40	0.0002	−3.43	0.0006

 Lysozyme 2	lyz2	2.99	0.0019	−2.31	0.004

 Lymphocyte antigen 96	ly96	1.71	0.003	−1.38	0.04

Interleukin 10 receptor beta	il10rb	1.75	0.004	−1.80	0.004

 Serum amyloid A 1	saa1	3.74	0.0004	−1.70	0.006

 Secreted phosphoprotein 1	spp1	2.44	0.001	−1.80	0.005

 Allograft inflammatory factor 1	aif1	1.95	0.0001	−2.82	0.00006

 Apoptotic peptidase activating factor 1	apaf	1.05	0.05	−1.05	0.05

Cytoskeleton

 Tubulin, beta 2A	tubb2a	−2.49	0.001	1.56	0.002

 Vinculin	vcl	−1.49	0.003	1.31	0.06

 MAP/microtubule affinity-regulating kinase 2	mark2	−1.52	0.01	1.34	0.05

 Actin, beta	actb	1.65	0.0006	−1.58	0.0001

 Serine/threonine kinase 11	stk11	−1.38	0.019	1.36	0.05

 Myosin IB	myo1b	1.43	0.05	−1.37	0.03

Intercellular junctions

 Claudin 1	cldn1	−1.04	0.21	−1.23	0.18

 Claudin 7	cldn7	1.48	0.003	−1.15	0.12

 Claudin 14	cldn14	2.37	0.0006	−1.78	0.0003

 Junction adhesion molecule 2	Jam2	1.23	0.03	−1.60	0.006

 Cadherin 5	cdh5	1.70	0.0006	−1.80	0.0001

 Desmocollin 2	dsc2	1.46	0.003	−1.46	0.001

Extracellular matrix

 Integrin beta 2	itgb2	−2.46	0.0006	2.03	0.0001

 Connective tissue growth factor	ctgf/bp8	−1.60	0.001	−1.57	0.006

 Proteoglycan 4	prg4	2.21	0.006	−2.24	0.0001

 Collagen, type I, alpha 2	col1a2	−1.58	0.001	1.13	0.02

 Collagen, type III, alpha 1	col3a1	−1.71	0.0003	1.08	0.38

 Collagen, type V, alpha 2	col5a2	1.66	0.0001	−3.99	0.0006

 Fibronectin 1	fn1	1.50	0.005	−1.45	0.003


Animal	Model	Preconditioning time/approach	TLR/ischemia	Result and mechanism	Author	Reference

Mice	MCAO, 60-min ischemia, 24-h reperfusion	72 h/12-min ischemia	Ischemic preconditioning	Decrease brain infarction volume, and IRF gene participate in brain protection	Stevens SL	[79]

Mice	MCAO, 60-min ischemia, 6-h reperfusion	24 h/IP	TLR2, Pam3CSK4	Decrease brain infarction and edema, improve neurological function, and maintain BBB function	Hua F	[60]

Mice	MCAO, 45-min ischemia, 24-h reperfusion	72 h/subcutaneous injection	TLR3, poly-ICLC	Decrease brain infarction volume and improve neurological function	Packard AEB	[63]

Mice	MCAO, 120-min ischemia, 22-h reperfusion	24 h/systemic injection	TLR3 poly-IC	Decrease brain infarction volume and neurological defect and lower the levels of TNF-α and IL-6 in cortex and striatum	Pan LN	[66]

Mice	MCAO, 60-min ischemia, 24-h reperfusion	1 h/IP	TLR3 poly-IC	Decrease brain infarction and prevention of Fas/FADD interaction	Zhang X	[67]

Spontaneously hypertension rats	MCAO, 120-min ischemia, 22-h reperfusion	2, 3, 4 days/IV	TLR4 LPS	Decrease brain infarction volume, mediated by TNF-α	Tasaki K	[72]

Mice	MCAO, 120-min ischemia, 47-h reperfusion	48 h/IP	TLR4 LPS	Decrease brain infarction volume, inhibit the infiltration of neutrophil and activation of the microglia	Rosenzweig HL	[73]

Mice	MCAO, 40-, 45-, 60-min ischemia, 24-h reperfusion	72 h/IP	TLR4 LPS	Decrease brain infarction volume that was mediated by IRF3	Marsh B	[61]

Mice	MCAO, 40-to 60-min ischemia, 24-h reperfusion	72 h/subcutaneous injection	TLR4 LPS	Decrease brain infarction volume, and TRIF-IRF3 play vital role	Vartanian KB	[58]

Mice	MCAO, 60-min ischemia, 24-h reperfusion	72 h/IP	TLR4	Decrease brain infarction volume, and inhibit TNF-α signaling pathway after cerebral ischemia	Rosenzweig HL	[76]

Mice	MCAO, 45-to 60-min ischemia, 23-h reperfusion	72 h/subcutaneous injection	TLR7 GDQ	Decrease brain infarction volume and neurological functional score that was protected through I type interferon	Leung PY	[62]

Mice	MCAO, 60-min ischemia, 72-h reperfusion	30 min/IV	TLR8 R848	Increase neurological function defect and mortality, activate pro-apoptotic JNK pathway and inflammation	Tang SC	[56]

Mice	MCAO, 60-min ischemia, 24-h reperfusion	72 h/IP	TLR9 CpG-ODN	Decrease brain infarction volume and TNF-α play a vital role	Stevens SL	[64]

Mice	MCAO, 60-min ischemia, 24-h reperfusion	72 h/IP or subcutaneous injection	TLR9 CpG-ODN	Decrease brain infarction volume and IRF gene participate in cerebral protection after ischemia	Stevens SL	[79]

Mice	MCAO, 60-min ischemia, 24-h reperfusion	1 h/IP	TLR9 CpG-ODN	Decrease brain infarction and activation of PI3K/Akt signaling	Lu C	[78]


Sl. number	Age	Gender	Site	Size	Histopathological category

Case1	40	Female	Gingiva	1-2 cm	Cellular phase

Case2	40	Female	Buccal mucosa	1-2 cm	Capillary phase, LCH type

Case3	09	Male	Buccal mucosa	<1 cm	Capillary phase, non-LCH type

Case4	23	Female	Gingiva	1-2 cm	Involutionary phase


Factors	Moxi	(%)	Non-Moxi	(%)

Number	276	 	1992

Age	44.78	 	38.5

Sex (male)	150	(54.3)	1129	(56.7)

Site of disease

Pulmonary	165	59.8	1182	59.3

Meningeal	12	4.3	9	0.5

Central Nervous System	2	0.7	4	0.2

Ocular	10	3.6	12	0.6

Other extra-pulmonary	87	31.5	786	39.4

Country of origin

Australian	22	8.0	219	11.0

Overseas	254	92.0	1773	89.0

HIV status

Positive	5	1.8	32	1.6

Negative	67	24.3	328	16.5

Unknown	204	73.9	1632	81.9

Diagnosis method

Culture	217	78.6	1521	76.3

Histological	13	4.7	161	8.1

PCR/NAT	19	6.9	116	5.8

Radiological	9	3.3	126	6.3

Clinical	17	6.2	58	2.9

Microscopic Examination	1	0.4	10	0.5

Sensitivities - Of culture positive cases

Fully sensitive	148	68.2	1410	92.6

MDRTB	39	18.0	0	0.0

XDRTB	2	0.9	0	0.0

Other resistance patterns	26	12.0	103	6.8

 Isoniazid Resistance	24	92.3	97	94.2

 Rifampicin resistance	1	3.8	0	0.0

 Pyrazinamide resistance	1	3.8	2	1.9

 Ethambutol resistance	0	0.0	3	2.9

 Other agents	0	0.0	1	1.0

Sensitivity results pending	2	0.9	9	0.6


FGD content analysis	Men – young FGD

Meaning unit	I think smoking is not related to sugar disease but there must be small part that can affect sugar disease; most smokers, including me, we usually deny

Condensed meaning unit	Smoking is related to diabetes ‘but small part’; smokers deny bad effect of smoking;

Codes	Smoking only partly related to diabetes

Smokers deny bad effect of smoking

Aware of healthy lifestyle but ignoring

Codes cluster	Diabetes content area:

-

Risk factors content area:

Smoking only partly related to diabetes

Smokers deny bad effect of smoking

Aware of healthy lifestyle but ignoring


Ligand	Mutagenicity	Carcinogenicity

	Salmonella typhimurium(CPDB)	Salmonella typhimurium(Kazius/Bursi)	Rodent(multiple sex)	Rat(both sex)	Mouse(both sex)

SAHA	no	no	no	no	yes

1a	no	no	no	no	no

1b	no	no	no	no	yes

1c	no	no	no	no	no

1d	no	no	no	no	no

1e	no	no	yes	no	no

1f	no	no	no	no	no

2a	no	no	no	no	yes

2b	no	no	no	no	yes

2c	no	no	no	no	yes

2d	no	no	no	no	yes

2e	no	no	no	no	yes

2f	no	no	no	no	yes


Variable	n(%) n = 105

Age (mean(SD))	63.4 (20.1)

Age category	-

20–49	24(23)

50–74	38(36)

75–84	25(24)

85+	18(17)

Female	67(64)

Secondary care antibiotic use	77(73)

Trimethoprim 1	63(82)

Co-amoxiclav 1	22(29)

Amoxicillin 1	66(86)

Nitrofurantoin 1	3(4)

Visited hospital in previous 12 months	53(50)

Antibiotic use in previous 12 months	-

Yes	21(20)

Unknown 2	79(75)

Co-morbidity	-

Asthma	14(13)

Diabetes mellitus	16(15)

COPD	3(3)

History of smoking	46(44)


	Effect	β	SE	P-Value

MVPA	Intercept	3.233	0.397	<0.001

	Maturity Offset	−0.077	0.098	0.434

	Maturity Offset* Maturity Offset	0.026	0.009	0.005

	Sex (ref = girl)	1.574	0.335	<0.001

	Family Support	0.677	0.128	<0.001

	Maturity Offset* Family Support	−0.080	0.028	0.004

	Family Support* Sex (ref = girl)	−0.298	0.118	0.012

	Friend Support	0.267	0.055	<0.001

	Mother’s Ed	0.355	0.192	0.065

MVPA-	Intercept	2.070	0.274	<0.001

PM Weekday	Maturity Offset	−0.251	0.050	<0.001

	Maturity Offset* Maturity Offset	0.026	0.009	0.004

	Sex (ref = girl)	0.385	0.126	0.002

	Family Support	0.315	0.065	<0.001

	Friend Support	0.352	0.056	<0.001

	Mother’s Ed	0.455	0.194	0.019


Run (session)	Total Samples	Average Strokes per Minute (SPM)	Number of Observation slices	Type of run

A	6,500	33.4	13	inner-club competition

B	8,000	15.4	8	training

C	4,500	32.0	9	inner-club competition

D	5,000	31.2	10	inner-club competition

E	8,000	15.0	8	recovery


Characteristics	Mean (SD); n (%)	Range:

Age in years	77.7 (5.89)	66-90

Women	25 (45.5%)	N/A

At least 1 fall in last 12 months	14 (25%)	N/A

BMI	25.8 (4.4)	14-42

Years of education	12.1 (3.4)	(8-20)

Cognition

 MMSE Score (0-30)	26.8 (2.1)	21-30

 MoCA score	22.4 (3.2)	15-28

 Letter Number Sequencing (LNS)	7.6 (2.4)	3-13

 TMT A (seconds)	55.8 (20.9)	23-102

 TMT B (seconds)	178.8 (108.6)	55-539

 Digit Symbol Coding	41 (14.4)	19-71

Gait Velocity (m/s)

 Single Gait Velocity (sGV)	0.87 (0.2)	0.44-1.50

 Verbal Gait Velocity (vGV)	0.65 (0.2)	0.32-1.00

 Counting Gait Velocity (cGV)	0.63 (0.2)	0.34-1.06


Name	Sel	Rec	VRec	VarN	M	MM	CEM	Seq	Tree	Ref

FPG	Yes	Yes	No	No	Yes	No	No	Yes	No	JH

EasyPop	No	Yes	No	No	Yes	Yes	No	No	Yes	B01

SimuPop	Yes	Yes	Yes	Yes	Yes	Yes	No	No	Yes	P05

FREEGENE	Yes	Yes	Yes	Yes	Yes	No	No	No	No	H07

GenomePop	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	No	C08


 	Educational levels

Junior high school	High school	Junior or career college	University or higher education	P for trend

Men

 Number of subjects	10 350	8437	1074	1968

 Age, years	50.5	48.1	47.5	46.7	<0.001

 Previous history of stroke, ischemic heart disease, or cancer, %	3.6	3.0	2.8	2.3	<0.001

 Current drinker, %	64.3	69.3	65.1	65.9	0.006

 Current smoker, %	54.9	53.1	51.0	47.0	<0.001

 High perceived mental stress, %	20.0	29.3	33.9	43.8	<0.001

 Living with spouse, %	76.0	86.4	87.9	90.6	<0.001

 Full-time worker, %	96.0	97.4	97.8	97.8	<0.001

Women

 Number of subjects	12 624	8894	2305	504

 Age, years	50.7	48.0	46.3	45.7	<0.001

 Previous history of stroke, ischemic heart disease, or cancer, %	4.1	3.3	3.9	3.1	0.08

 Current drinker, %	9.0	11.0	11.0	10.2	<0.001

 Current smoker, %	7.6	6.8	6.5	6.5	0.02

 High perceived mental stress, %	18.5	22.8	29.3	40.9	<0.001

 Living with spouse, %	69.6	81.6	81.6	83.2	<0.001

 Full-time worker, %	74.0	76.7	76.5	85.9	<0.001


Participant characteristics	N (%)

Gender

 Men	1 (6)

 Women	16 (94)

Mean age (years)	38 (range 30–47)

Mean age of allergic children (years)	3 (range 0.5-10)

First health care contact

 Emergency Department	10 (59)

 Family Physician	4 (23)

 Other	3 (18)

Allergen associated with first reaction

 Tree nuts	6 (35)

 Peanuts	4 (24)

 Fish	2 (12)


Question	Percent of responses correct (2011–2012)	Percent of responses correct (2012–2013)	Percent of responses correct (2013–2014)

There is no cure for asthma	80.8	84.9	90.3

Although asthma causes breathing problems, asthma episodes are not dangerous	93.8	96.4	97.9

Taking medications every day can help prevent an asthma episode	–	87.9	86.5

A person should take steroids for asthma to grow muscle mass for better athletic ability	86.8	89.7	91.2

Inhaled steroids have the same side effects as steroids taken by mouth	55.0	68.5	66.8

Very little can be done to reduce environmental triggers of asthma	69.0	76.1	78.2

Asthma medications are not addictive	51.4	55.9	66.6

People with asthma should not participate in sports	97.2	96.4	98.2

Asthma episodes always occur suddenly, without warning	71.5	78.1	84.4

Asthma can be caused by emotional stress or other psychological problems	31.9	82.0	83.6

A rescue or reliever medication (albuterol) helps during an asthma episode by making you breathe faster	47.6	63.3	65.1


	No decrease in haemoglobin, n (%)	With a decrease in haemoglobin, n (%)

Celecoxib N = 872	841 (96.44)	31 (3.56)

Diclofenac N = 438	412 (94.06)	26 (5.94)

	OR = 1.71 (1.00–2.92)


 	NTM lung diseases patients (N = 84)	Non-NTM BE patients (N = 47)	P value

Any isolates	17 	(20.2%)	12 	(25.5%)	1.00

Single isolate in one patient	15 	(19.7%)	12 	(26.7%)	0.38

Klebsiella pneumoniae	4	(4.8%)	5	(10.6%)	0.28

Streptococcus pneumoniae	1	(1.2%)	1	(2.1%)	1.00

Streptococcus species, viridans group	1	(1.2%)	0	 	1.00

Methicillin-sensitive Staphylococcus aureus	1	(1.2%)	0	 	1.00

Methicillin-resistant Staphylococcus aureus	2	(2.4%)	0	 	0.54

Pseudomonas fluorescens	1	(1.2%)	0	 	1.00

Pseudomonas putida	1	(1.2%)	0	 	1.00

Pseudomonas aeruginosa	2	(2.4%)	5	(10.6%)	0.10

Aeromonas hydrophila	1	(1.2%)	1	(2.1%)	1.00

Neisseria species	1	(1.2%)	0	 	1.00

Multiple microorganisms	2 	(2.4%)	0 	 	0.54

Methicillin-sensitive Staphylococcus aureus and Pseudomonas fluorescens	1	(1.2%)	0	 	1.00

Methicillin-resistant Staphylococcus aureus and Klebsiellapneumoniae	1	(1.2%)	0	 	1.00


Disease condition	No (n, %)	Somewhat (n, %)	Yes (n, %)

Endocrine disorders (diabetes mellitus, thyroid disease)	81	36.7 %	65	29.4 %	75	33.9 %

Acute coronary syndrome	3	1.4 %	41	18.6 %	177	80.1 %

Hypertension	119	54.1 %	60	27.3 %	41	18.6 %

Thromboembolic disease (DVT and PE)	65	29.4 %	53	24.0 %	103	46.6 %

Asthma/COPD	192	86.9 %	18	8.1 %	11	5.0 %

Trauma	76	34.5 %	61	27.7 %	83	37.7 %

Partner abuse	6	2.7 %	48	21.7 %	167	75.6 %

Carotid/vertebral artery dissections	162	73.6 %	35	15.9 %	23	10.5 %

Neurologic conditions (multiple sclerosis, myasthenia gravis, CVA, seizures, headache)	67	30.3 %	60	27.1 %	94	42.5 %

GI conditions (biliary disease, dyspepsia, IBS, appendicitis, abdominal pain)	55	24.9 %	64	29.0 %	102	46.2 %

Substance abuse	121	55.0 %	63	28.6 %	36	16.4 %

Depression/suicide	39	17.8 %	51	23.3 %	129	58.9 %

Urinary tract disorders	18	8.1 %	45	20.4 %	158	71.5 %

Sexually transmitted diseases	25	11.3 %	49	22.2 %	147	66.5 %

HIV/AIDS	144	65.5 %	46	20.9 %	30	13.6 %

Autoimmune disease	27	12.3 %	67	30.5 %	126	57.3 %

Pulmonary disease (sarcoidosis, PPH)	129	58.4 %	53	24.0 %	39	17.6 %

Osteoporosis/fracture management	41	18.6 %	44	19.9 %	136	61.5 %

Pain management	150	68.2 %	44	20.0 %	26	11.8 %

Pharmacokinetics	135	61.4 %	63	28.6 %	22	10.0 %

Communication styles	60	27.1 %	81	36.7 %	80	36.2 %


	Explicit LearningGroup (n = 40)	Implicit Learning Group (n = 40)	ControlGroup (n = 40)

T1Intervention	30 side-step cutting trials -Detailed verbal instructions on performance will be given	30 side-step cutting trials - Best performance will be shown	30 side-step cutting trials -No feedback on performance will be given

T2Retention test (one week post intervention)	30 side-step cutting trials -No feedback on performance will be given	30 side-step cutting trials -No feedback on performance will be given	30 side-step cutting trials -No feedback on performance will be given

T3Retention test (one month post intervention)	30 side-step cutting trials -No feedback on performance will be given	30 side-step cutting trials -No feedback on performance will be given	30 side-step cutting trials -No feedback on performance will be given


Population/Gender (N)	G6PD variant allele frequency

	Mahidol	Viangchan	Chinese 4	Union	Canton	Kaiping	Gaohe

Thai

Male (84)	0.04	0.01	-	0.01	0.02	0.012	-

Female (233)	0.01	0.006	0.006	0.002	-	0.002	0.002

Burmese

Male (11)	0.18	-	-	-	-	-	-

Female (172)	0.07	-	-	-	-	0.003	-


Demographic information	Patients

Sex Ratio	12 women and 7 men

Age (years)	56 ± 8.96

Height (cm)	164.52 ± 5.09

Weight (kg)	76.52 ± 12.87

BMI (Kg/m2)	28.33 ± 4.65

Diabetic History (years)	11.84 ± 6.93


Axillary vs. tympanic temperature	Correlation Coefficient	Bias ± SD	95% CI	Limits of agreement

 	0.697	−0.093 ± 0.72	−0.20; 0.02	−1.54 to 1.36


Isolate	Geographic origin	Year	Sourcea	Alternative ID	GenBank/ EBI accession number

Rs 10	New Brunswick, Canada	2009	Salmo salar (sw)	 	ERR327945

Rs 2	New Brunswick, Canada	2005	S. salar (sw)	 	ERR327951

Rs 3	New Brunswick, Canada	2005	S. salar (fw)	 	ERR327947

Rs 4	New Brunswick, Canada	2006	S. salar (sw)	 	ERR327946

Rs 5	New Brunswick, Canada	2007	S. salar (sw)	 	ERR327950

Rs 6	New Brunswick, Canada	2007	S. salar (sw)	 	ERR327953

Rs 8	New Brunswick, Canada	2008	S. salar (sw)	 	ERR327944

BPS 91	Nanaimo, BC, Canada	1991	Oncorhynchus gorbuscha	 	ERR327952

BQ96 91-1	Nanaimo, BC, Canada	1996	Oncorhynchus kisutch	 	ERR327963

DR143	Alberta, Canada	1972	Salvelinus fontinalis (fw)b	 	ERR327954

5006	Bella Bella, BC, Canada	1996	O. kisutch (sw)	960046	ERR327942

5223	Kvinnherad, Hordaland, Norway	2005	S. salar (sw)	2005-50-579	ERR327964

6553	Hemne, Sør-Trøndelag, Norway	2008	S. salar (sw)	2008-09-495	ERR327955

6642	Hemne, Sør-Trøndelag, Norway	2008	S. salar	2008-06-633	ERR327956

6694	Hemne, Sør-Trøndelag, Norway	2008	Oncorhynchus mykiss (sw)	 	ERR327962

6695	Hemne, Sør-Trøndelag, Norway	2008	O. mykiss (sw)	2008-06-631	ERR327968

6863	Osterøy, Hordaland, Norway	2009	O. mykiss (sw)	 	ERR327965

7439	Sognefjorden, Sogn og Fjordane, Norway	1984	S. salar	1984-40.992	ERR327971

7441	Storfjord, Møre og Romsdal, Norway	1985	S. salar	1985-09-667	ERR327966

7448	Stranda, Møre og Romsdal, Norway	1986	S. salar	1986-09-4366	ERR327970

7449	Skjervøy, Troms, Norway	1987	S. salar	1987-09-932	ERR327969

7450	Askøy, Hordaland, Norway	1987	S. salar	1987-09-1185	ERR327967

684	Aurland, Sognefjorden, Norway	1987	S. trutta (fw)	 	ERR327958

1205	UK	2001	O. mykiss	3104-67	ERR327930

5007	Scotland	2005	O. mykiss	0180-18	ERR327923

7105	UK	2007	O. mykiss (fw)	P0416 T83 10-3 2	ERR327932

9025	Yorkshire, England, UK	2009	O. mykiss (fw)	16251-1	ERR327912

96071	England, Hampshire, site Z, UK	1996	O. mykiss (fw)	 	ERR327927

99326	Wales, site Y, UK	1999	O. mykiss (fw)	2119-8	ERR327938

99327	UK	1997	O. mykiss (fw)	970313-2	ERR327931

99329	Wales, site X, UK	1998	O. mykiss (fw)	980036-125	ERR327937

99332	Wales, site Y, UK	1999	O. mykiss (fw)	2119-3	ERR327943

99333	Wales, site X, UK	1998	O. mykiss (fw)	980036-102	ERR327921

99341	Hampshire, site Z, England, UK	1998	O. mykiss (fw)	980109-20	ERR327949

99344	Hampshire, England, UK	1998	O. mykiss (fw)	980106-1.1.5	ERR327940

99345	Wales, site X	1998	O. mykiss (fw)	980070-18	ERR327948

NCIMB 1114	River Dee, Scotland, UK	1962	S. salar (fw)b	5005	ERR327908

NCIMB 1116	River Dee, Scotland, UK	1962	S. salar (fw)b	96056	ERR327907

MT239	Scotland, UK	1988	S. salar	 	ERR327913

MT1363	Strathclyde, Scotland, UK	1993	O. mykiss (sw)	 	ERR327920

MT3277	Dumfries and Galloway Site A, Scotland,UK	2008	O. mykiss (fw)	 	ERR327926

MT3313	Central, Scotland, UK	2008	O. mykiss (fw)	 	ERR327925

MT3315	Strathclyde Site B, Scotland, UK	2008	O. mykiss (fw)	 	ERR327928

MT1262	Highlands, Scotland, UK	1992	S. salar (fw)	 	ERR327922

MT1351	Highlands, Scotland, UK	1993	S. salar (sw)	 	ERR327904

MT1470	Tayside, Scotland, UK	1994	O. mykiss (fw)	 	ERR327910

MT1511	Strathclyde Site B, Scotland, UK	1994	O. mykiss (fw)	 	ERR327914

MT1880	Strathclyde, Scotland, UK	1996	S. salar (sw)	 	ERR327909

MT2622	Strathclyde, Scotland, UK	2002	O. mykiss (sw)	 	ERR327929

MT2943	Highlands, Scotland, UK	2005	S. salar (sw)	 	ERR327936

MT2979	Highlands, Scotland, UK	2005	O. mykiss (fw)	 	ERR327935

MT3106	Strathclyde, Scotland, UK	2006	O. mykiss (fw)	 	ERR327939

MT3479	Orkney, Scotland, UK	2008	S. salar (sw)	 	ERR327933

MT3482	Strathclyde, Scotland, UK	2009	S. salar (sw)	 	ERR327934

MT3483	Strathclyde, Scotland, UK	2009	S. salar (sw)	 	ERR327941

MT444	Western Isles, Scotland, UK	1988	S. salar (sw)	 	ERR327916

MT452	Dumfries and Galloway Site A, Scotland,UK	1988	O. mykiss (fw)	 	ERR327918

MT839	Highlands, Scotland, UK	1990	S. salar (sw)	 	ERR327917

MT861	Scotland	1990	S. salar (sw)	 	ERR327919

Car 96	Washington State, USA	1996	O. tshawytscha	 	ERR327957

D6	Oregon, USA	1982	O. tshawytscha	 	ERR327961

GR5	Montana, USA	1997	T. thymallus (fw)b	980036-87	ERR327959

WR99 c2	Washington State, USA	1999	O. kisutch	 	ERR327960

NCIMB 2235	Oregon, USA	1974	O. tshawytscha (sw)	ATCC33209	ERR327911

05372K	Grande Ronde Basin, Oregon, USA	2005	O. tshawytscha (sw)	 	ERR327906

Carson 5b	Confluence Tyee Creek & Wind River, WA, USA	1994	O. tshawytscha (fw)	 	ERR327905

Cow-chs-94	Cowlitz River, Washington	1994	O. tshawytscha (fw)	 	ERR327915

ATCC 33209c	Oregon, USA	1974	O. tshawytscha (sw)	 	NC_010168.1

NCIMB 1111d	—	Not known	Not known	5004	ERR327924


Location, study period (reference)	PM size	Type of fuel	Mean (μg/m3)	Notes

China

Shenyang, China, May 2006 (this study)	PM10	Crop residue	Total: 100.6Cooking times: 202.1	Based on ~14 hr/day (0530–1930) for 5 consecutive days3 households

Jilan, China, Nov–Dec 2001, Feb–Mar 2003, 2004 (Fischer and Koshland 2007)	PM4	Multiple fuels: coal, biomass, gas, electricity	Daily average: 3121-hr peak: 1,880	Based on 24-hr periods and 1-hr peak values70 household-days37 households

Gansu, China, Mar–Apr 2003, Dec 2003–Jan 2004 (Jin et al. 2005)	PM4	Wood and crop residue	Mar–Apr 2003: 518Dec 2003–Jan 2004: 661	Based on 24-hr/day periodsMar–Apr 2003: 72 households with 1 day of measurement, 6 households with 4 days of measurementDec 2003–Jan 2004: 17 households with 1 day of measurement, 6 households with 2–3 days of measurement

Guizhou, China, Mar–Apr 2003, Dec 2003–Jan 2004 (Jin et al. 2005)	PM4	Coal, wood, and crop residue	Mar–Apr 2003: 352Dec 2003–Jan 2004: 301	Based on 24-hr/day periodsMar–Apr 2003: 76 households with 1 day of measurement, 7 households with 2–4 days of measurementDec 2003–Jan 2004: 16 households with 1 day of measurement, 6 households with 2–3 days of measurement

Inner Mongolia, China, Dec 2003–Jan 2004 (Jin et al. 2005)	PM4	Wood and crop residue	718	Based on 24-hr/day periods49 households with 1 day of measurement, 4 households with 3 days of measurement

Shaanxi, China, Mar–Apr 2003, Dec 2003–Jan 2004 (Jin et al. 2005)	PM4	50% coal, 50% wood and crop residue	Mar–Apr 2003: 187Dec 2003–Jan 2004: 223	Based on 24-hr/day periodsMar–Apr 2003: 75 households with 1 day of measurement, 6 households with 4 days of measurementDec 2003–Jan 2004: 18 households with 1 day of measurement, 6 households with 3 days of measurement

Guizhou, China, Jan 2003 (He et al. 2005)	PM4	Coal (3 households), coal and biomass (1 household)	1,944	Based on 24-hr/day periods for 4 consecutive days4 households

Shaanxi, China, Feb 2003 (He et al. 2005)	PM4	Coal and biomass for cooking, coal for heating	205	Based on 24-hr/day periods for 4 consecutive days4 households

Zhejiang, Hubei, and Shaanxi, China, Jun–Aug 2002, Dec 2002–Jan 2003 (Edwards et al. 2007)	PM4	Crop residues	Summer: 282.9Winter: 456.4	Based on 24-hr periods48 households for summer, 25 for winter

Bolivia

Cantuyo, Jan 1994–Oct 1995 (Albalak et al. 1999)	PM10	Dung	1,830	Based on 6-hr periods (0500–1100)/day every 6 days for 3 consecutive weeks for each month of study period12 households

India

Pauri District, Garhwal Himalaya, northern India, Aug 1989–Jul 1990 (Saksena et al. 1992)	TSP	Wood	Cooking times: 5,600Noncooking times: 820	Based on 15-hr periods12 households

Tamil Nadu, southern India, Jul–Dec 1999 (Balakrishnan et al. 2002)	PM4	Wood and crop residue	Indoor kitchen without partitions: 1,442Kitchen with partitions: 970	Based on 10- to 12-hr/day periods for 1–3 daysWithout partitions: 105 householdsWith partitions: 68 households

Andhra Pradesh, southern India, Jan–May 2001 (Balakrishnan et al. 2004)	PM4	WoodDung	Wood: 500Dung: 732	Based on 22- to 24-hr/day sampling periods for 3–4 daysWood: 270 householdsDung: 97 households

Guatemala

Quetzaltenango, May–Nov 1993 (Naeher et al. 2000)	PM2.5PM10TSP	Wood	PM2.5: 527.9,a 96.5bPM10: 717.1,a 186.3bTSP: 835.8,a 275.5b	Based on three 22-hr sampling periods3 households

La Victoria, Jan 1999 (Bruce et al. 2004)	PM3.5	Wood and crop residue	1,019a351b	Based on one 24-hr measurement/ household11 households with open fires, 5 with planchas

La Victoria, Dec 1998–Jul 1999 (Albalak et al. 2001)	PM3.5	Wood	1,560a280b	Based on 24-hr measurements taken 6 times at 1-month intervals10 households of each stove type


AGI	Annotation	P-score	References

AT2G30870	ERD13, glutathione-S-transferase PHI 10	32	Ryu et al. (2009), Carter et al. (2004) and Marmagne et al. (2007)

AT2G45820*	Remorin, putative DNA-binding protein, salt-induced	22	Benschop et al. (2007), Nelson et al. (2006) and Kreps et al. (2002)

AT1G04690	KAB1, KV-BETA1 (potassium channel beta subunit)	18	Maathuis (2006)

AT3G18240*	Unknown protein, phosphorylated	18	de la Fuente van Bentem et al. (2008)

AT1G53070*	Legume lectin family protein, cell wall asscociated	15

AT1G09210*	CRT2, Calreticulin 2; calcium ion binding	13	Jiang et al. (2007)

AT1G56340*	CRT1, Calreticulin 1; calcium ion binding	12	Jiang et al. (2007)

AT5G38480*	GRF3, 14-3-3 PSI, overexpression confers salt tolerance	9	Marmagne et al. (2007) and Du et al. (2008)

AT3G02750*	PP2C, protein phosphatase 2C family, group E	9	Bassel et al. (2008)

AT5G19440	CAD, Cinnamyl-alcohol dehydrogenase, putative	9	Marmagne et al. (2007)

AT3G18820	RAB71, (Arabidopsis RAB GTPase homolog G3F); GTP binding	8	Marmagne et al. (2007)

AT2G02990	RNS1, (Ribonuclease 1); cell wall/plasma membrane associated	8

AT1G02090*	CSN7, MAP kinase kinase; subunit of COP9 signalosome	7

AT5G16050*	GRF5, 14-3-3 UPSILON (general regularory factor 5)	6	Marmagne et al. (2007)

AT2G43940	Thiol methyltransferase, putative, chloroplast envelope	6

AT5G07340	Calnexin, putative, vacuolar	6	Schmidt et al. (2007)

AT1G28200	FIP1 (FH interacting protein 1), VirF-interacting protein FIP1	5

AT1G78300	GRF2, 14-3-3 OMEGA, (general regularory factor 2)	5	Chang et al. (2009)

AT3G06300	P4H-2, (prolyl-4-hydroxylase, isoform 2); endomembrane system	5

AT1G77120*	ADH1, (alcohol dehdrogenase 1); salt stress-responsive	5	de la Fuente van Bentem et al. (2008) and Jiang et al. (2007)

AT5G67500	VDAC2 (voltage-dependent anion channel 2), seedling development	5	Yan et al. (2009) and Lee et al. (2009)

AT3G01280	VDAC1 (voltage-dependent anion channel 1)	5	Lee et al. (2009)

AT1G74020	SS2 (STRICTOSIDINE SYNTHASE 2); strictosidine synthase	5	Marmagne et al. (2007)

AT4G17720*	RNA recognition motif (RRM)-containing protein, phosphorylated	5	de la Fuente van Bentem et al. (2006)

AT4G18800	RABA1D (Arabidopsis RAB GTPase homolog A1D);	5	Marmagne et al. (2004)

AT3G61990	O-methyltransferase family 3 protein, cytosolic	4

AT1G22280*	PAPP2C, phytochrome-associated protein phosphatase 2C; group F	4	de la Fuente van Bentem et al. (2008) and Phee et al. (2008)

AT3G15260*	PP2C, protein phosphatase 2C family, group F	4


Variable	OR	p	95% conf. interval

Received blood transfusion

Age	1.12	<0.01	1.06–1.19

Sex	1.35	0.32	0.74–2.46

Bilirubin	0.81	0.01	0.69–0.95

No blood transfusion

Age	1.01	0.85	0.94–1.07

Sex	1.80	0.06	0.98–3.29

Bilirubin	0.86	0.20	0.69–1.08


Treatment	Vehicle control	Positive control MMC(0.20 μg/mL)	NR-INF-02(2500.00 μg/mL)	NR-INF-02(791.14 μg/mL)	NR-INF-02(250.36 μg/mL)

R1	R2	R1	R2	R1	R2	R1	R2	R1	R2

Total number of metaphase analyzed	100	100	100	100	100	100	100	100	100	100

Normal	99	100	92	92	98	97	98	96	98	100

Chromatid break	1	—	—	4	1	—	1	—	—	—

Chromosome break	—	—	—	1	—	1	—	—	—	—

Deletion	—	—	—	1	—	—	—	—	1	—

Ring	—	—	3	1	1	—	—	—	1	—

Dicentric	—	—	5	1	—	2	—	1	—	—

Fragment	—	—	—	—	—	—	—	1	—	—

Gap	—	—	—	—	—	—	1	1	—	—

Ploidy	—	—	—	—	—	—	—	1	—	—

Endoreduplication	—	—	—	—	—	—	—	—	—	—

Total aberrations	1	0	8	8	2	3	1	1	2	0

Total aberrations (Mean ± SD)	0.50 ± 0.70	8.00 ± 0.00*	2.50 ± 0.70	1.0 ± 0.00	1.00 ± 1.41

Mitotic Index (Mean ± SD)	5.35 ± 0.49	2.63 ± 0.10*	3.75 ± 1.06	4.25 ± 0.35	4.0 ± 0.42


Protein Name	Uniprot ID	Function	Up- or downregulateda

DNA-dependent protein kinase catalytic subunit	P78527	Serine/threonine-protein kinase, molecular sensor for DNA damage.	Up

Lumican	P51884	Collagen fibril organization, epithelial cell migration and tissue repair.	Down

Tetranectin	P05452	Binds plasminogen and isolated kringle 4. Packaging molecules for exocytosis.	Down

Gelsolin	P06396	Key regulator of actin filament assembly and disassembly.	Down

Cartilage acidic protein 1	Q9NQ79	Upregulated by BMP4 in mesenchymal stem cells undergoing chondrogenic differentiation.	Down

Matrin-3	P43243	Transcription and interaction with other nuclear matrix proteins to form the internal fibrogranular network.	N/A

Glucose-6-phosphate isomerase	P06744	Glycolytic enzyme and angiogenic factor (AMF) that stimulates endothelial cell motility.	N/A

Coactosin-like protein	Q14019	Binds to F-actin in a calcium-independent manner.	N/A

Peptidyl-prolyl cis-trans isomerase A	P62937	Accelerates the folding of proteins.	N/A

Myeloperoxidase	P05164	Produces hypochlorous acid (HOCl) used by the neutrophils to kill bacteria and other pathogens.	N/A

Golgin subfamily B member 1	Q14789	Forms intercisternal cross-bridges of the Golgi complex.	N/A

2′-deoxynucleoside 5′-phosphate N-hydrolase 1	O43598	Catalyses cleavage of the N-glycosidic bond of deoxyribonucleoside 5′-monophosphates.	N/A


 	Group P (n = 13)	Group R(n = 28)	P value

Mean decrease in Hb† (g/dL ± SD‡)	0.21 ± 0.66	0.37 ± 0.67	0.55

Mean procedure time (min ± SD)	87.5 ± 51.3	99.5 ± 46.1	0.28

Incidence of perforation, % (n)	0.0 (0)	3.6 (1)	0.49

Incidence of clip use, % (n)	38.5 (5)	57.1 (16)	0.27

Incidence of muscle injury, % (n)	15.4 (2)	28.6 (8)	0.36

Incidence of postoperative fever, % (n)	7.7 (1)	10.7 (3)	0.76

Incidence of postoperative bleeding, % (n)	0.0 (0)	3.6 (1)	0.49

Percentage of patients who resumed eating on the day after ESD, % (n)	76.9 (10)	82.1 (23)	0.81


Material	Thermal conductivity	Specific heat	Density	Electrical conductivity

k(W/m⋅K)	c(J/kg⋅K)	ρ(kg/m3)	σ(S/m)

Plastic	0.026	1045	70	10-5

Electrode	70	840	6450	108

Saline	0.58	3200	1004	a(3)

Hepatic tissue	0.502	3455 (1)	1080 (1)	b(3)

2155 (2)	370.44 (2)


	Mean genome size (1C; pg)

	*R1	*R2	*R3	Mean ± SD

Lestrimellita sp (diploid males)	0.460	0.465	0.465	0.463 ± 0.003

Lestrimellita sp (females)	0.455	0.465	0.470	0.463 ± 0.008


Gestational age	n	Colonization with enterococci	Colonization with multidrug-resistant enterococci	% multidrug-resistant enterococci

All patients	274	63 (22.9%)	36 (13.1%)	57.1%

≥ 37 weeks of gestation	117	24 (20.5%)	10 (8.5%)	41.7%

32 – 36 weeks of gestation	94	18 (19.1%)	7 (7.4%)	38.9%

< 32 weeks of gestation	63	21 (33.3%)	19 (30.2%)	90.5%


Characteristic	Partial helmet law	Universal helmet law	P-value*

Number of motorcycle operators	N = 28,207	N = 45,552

Helmet used	42 %	88 %	<0.01

Age (Median)	37	36	0.52

Male	93 %	93 %	0.77

Single Vehicle Crash	39 %	45 %	<0.01

Crash at Intersection	36 %	40 %	<0.01

Night time	18 %	17 %	<0.01

Speed relateda	10 %	17 %	<0.01

Suspicion of alcohol or drugsa	9 %	5 %	<0.01

Rural locationa	17 %	31 %	<0.01

Poor Surface Conditions	6 %	7 %	<0.01

Crash record linked to a medical record	55 %	58 %	<0.01

Died at the scene	3 %	3 %	0.62


Practitioners	Patients

1) Theoretical Stance	1) Reasons for Therapy

A) Integrity of Self	A) specific, individual reason based on symptoms, illness, or sense of dis-ease

B) Human Capacity for Embodiment	B) motivational drive to seek new resources for active coping

C) Central Role Of Embodiment And Integrity Of Self To The Practice

2) The Practice	2) Engagement in the practice and what happens from the patients' point of view

A) Breath and Breathing	A) Process

B) Repetition and Training	B) Shift in Awareness

	a) Negative Emotion

	b) Body Sensation

C) Noticing/Discriminating/Discerning	C) Engagement in

	a) Self Regulation

	b) Self Care

D) Goal of Practice: Integration of Mind, Body and Life Context	D) Integration of Mind, Body and Life Context

	a)Context

	b) Mind-Body Integration


Characteristics	No (%)

<underline>Age (years)</underline>

20–24	9 (27.3)

25–34	9 (27.3)

35–49	12 (36.3)

>50	3 (9.1)

<underline>No. of years working as applicator</underline>

2 to 5	16 (48.5)

6 to 9	4 (12.1)

10 to 20	10 (30.3)

>20	3 (9.1)

<underline>Protective measure in use</underline>

Boots	8 (24)

Apron	1 (3)

Mask	2 (3)

Gloves	0 (0)

Glasses	2 (6)

Respirator	2 (6)

Plastic for the back	15 (46)

Waterproof garment	1 (3)


Period	Ticks collected	Animals inspected	Infestation rate (%)

May-June (2014)	600	87	71

July-August	370	77	69

September-October	231	77	58

November-December	201	47	60

January-February (2015)	159	55	49

March-April	377	75	64

Total (over year)	1,938	418	63


Scheme sponsorship	State	Recruitment method	Code

Private	Victoria	Direct contact with researcher	E1

Private	Victoria	Scheme	E2

Private	Victoria	Scheme	E3

Private	Victoria	Scheme	E4

Private	Victoria	Scheme	E5

Private	Victoria	Scheme	E6

Private	Queensland	Scheme	E7

Private	Queensland	Scheme	E8

Private	Queensland	Scheme	E9

Not-for-profit	Victoria	Direct contact with researcher	E10

Not-for-profit	Victoria	Scheme	E11

Not-for-profit	Victoria	Scheme	E12

Not-for-profit	Victoria	Scheme	E13

Not-for-profit	Victoria	Scheme	E14

Not-for-profit	Victoria	Scheme	E15

Not-for-profit	Queensland	Direct contact with researcher	E16


	<underline>Model</underline>	<underline>Terms</underline>

<underline>Overall</underline><underline>Accuracy</underline>	R2 =	p <		Tones	Clicks	Gabors	Music

Language ~ Tones + Clicks + Gabors	0.671	0.001	β =	0.495	0.505	0.054	−

			p =	0.054	0.155	0.786	−

Language ~ Tones + Clicks + Gabors + Music	0.919	6×10-7	β =	0.181	0.261	-0.023	0.655

			p =	0.191	0.165	0.822	3×10-5

<underline>Sensitivity</underline><underline>(</underline><underline>A</underline>'<underline>)</underline>

Language ~ Tones + Clicks + Gabors	0.646	0.002	β =	0.302	0.435	0.229	−

			p =	0.139	0.119	0.323	−

Language ~ Tones + Clicks + Gabors + Music	0.923	5×10-7	β =	0.065	0.273	0.071	0.696

			p =	0.525	0.055	0.533	2×10-5

<underline>Threshold</underline>

Language ~ Tones + Clicks + Gabors	0.606	0.004	β =	0.636	0.520	0.090	−

			p =	0.068	0.030	0.706	−

Language ~ Tones + Clicks + Gabors + Music	0.846	4×10-5	β =	0.287	0.092	0.009	0.599

			p =	0.220	0.595	0.956	6×10-4


Connection Resiliency	Self-Powered WSN	MEDiSN

Failure Sequences	Elapsed Time (s)	Failure Sequences	Elapsed Time (s)

1	24	1500	18	600

2	552	9720	306	2160

3	12,144	32,580	4896	2820


Subscale/Criterion	Factor

	1	2	3

SAWS critical life experience	0.047	0.702	0.220

SAWS emotional regulation	0.165	0.869	−0.007

SAWS reminiscence and reflectiveness	0.119	0.814	−0.230

SAWS openness	0.115	0.410	0.682

SAWS humor	0.174	0.589	0.277

ASTI	0.303	0.580	0.565

3D-WS reflective dimension	0.218	−0.022	0.782

3D-WS affective dimension	−0.016	0.202	0.833

3D-WS cognitive dimension	0.372	−0.205	0.753

BWP uncertainty	0.711	0.209	−0.123

BWP value relativism	0.758	0.052	0.127

BWP contextualism	0.850	0.149	0.104

BWP factual knowledge	0.865	0.093	0.268

BWP procedural knowledge	0.743	0.133	0.408


Wound Infections	Non-Wound Infections

Cellulitis/Abscess (11/31)	Seromas (20/31)

Pre-Operative Prophylactic Antibiotics

Cefazolin 8/11 (73%)	Cefazolin 16/20 (80%)

Clindamycin 1/11 (9%)	Clindamycin 3/20 (15%)

Vancomycin 1/11 (9%) (plus gentamicin)	Vancomycin 0/20 (0%)

Unknown 1/11 (9%)	Unknown 1/20 (5%)

The Relationship between Pre-Operative Antibiotics and Post-Operative Wound Cultures

Cefazolin (8/11)	Cefazolin

associated isolates *:	associated isolates *:

MSSA = 3	CoNS = 6

MRSA = 2	MSSA = 1

M. fortuitum = 1	VSE = 1

Unknown = 2	E. coli = 2

Clindamycin	Proteus sp. = 1

associated isolates:	Unknown = 2

E. coli = 7	Culture negative = 7

Vancomycin (1/11) (plus gentamicin)	Clindamycin

associated isolates:	associated isolates:

K. pneumoniae = 2	CoNS = 2

	Culture negative = 2


	CYP transcripts of O. sanctum	CYP transcripts of O. basilicum	Functions

Arabidopsisannotation	Lamiaceae annotation	Arabidopsisannotation	Lamiaceae annotation

CYP72A14	2	-	8	-	Phenylpropanoid Metabolism

CYP73A1	5	7	23	33	Cinnamate 4-hydroxylase (C4H)

CYP75B1	8	-	8	-	Flavonoid biosynthesis

CYP81D1	2	-	16	-	Phenylpropanoid Metabolism

CYP81F3	1	-	9	-	Phenylpropanoid Metabolism

CYP84A1	2	-	1	-	Coniferaldehyde 5-hydroxylase

CYP93D1	-	-	1	-	Phenylpropanoid Metabolism

CYP98A3	12	-	25	-	4-Coumaryl shikimic/quinic ester 3′-hydroxylase.

CYP98A14	-	16	-	46	p-Coumaryl shikimate hydroxylase

CYP707A2	5	-	4	-	Phenylpropanoid Metabolism (abscisic acid 8′-hydroxylase)

CYP707A3	12	-	13	-	Secondary metabolism (abscisic acid 8′-hydroxylase)

CYP710A1	3	-	7	-	Phenylpropanoid Metabolism

CYP711A1	1	-	1	-	Core phenylpropanoid metabolism

CYP712A1	-	-	2	-	Stilbene, coumarine and lignin biosynthesis


i) 7 weeks old

 	 	+/+	m1/+	m1/m1

No. of transplantation	9	24	10

Tumor developed	9	24	4

Dead or degrading	0	0	6*

<underline>Tumor size</underline>

large (1.0 - 2.0 cm)	8	24	0

middle (0.5 - 1.0 cm)	1	0	0

small (< 0.5 cm)	0	0	4

<underline>Differentiation</underline>

Ectoderm	9	24	4

Mesoderm	8	21	0

Endoderm	4	14	2

ii) 1 week old

 	 	+/+	m1/+	m1/m1

No. of transplantation	3	8	5

Tumor developed	3	7	5

Dead or degrading	0	1	0

<underline>Tumor size</underline>

large (1.0 - 2.0 cm)	0	0	0

middle (0.5 - 1.0 cm)	2	5	0

small (< 0.5 cm)	1	2	5

<underline>Differentiation</underline>

Ectoderm	3	7	0

Mesoderm	2	5	0

Endoderm	2	4	0


Organism	Common name	Group	Annotation status

Acanthamoeba castellanii	Amoeba	BCM-HGSCa	Server set up in progress

Helicoverpa armigera	Cotton bollworm	CSIROb	Server set up and analysis in progress

Pythium ultimum	Pythium blight	GMOD	Used one contig to teach a GMOD course

Zea maize	Corn	Iowac	Server set up in progress

Manduca sexta	Goliath moth	Kansasd	Server set up in progress

Mayetiola destructor	Hessian fly	Kansas	Server set up and analysis in progress

Acromyrmex echinatior	Leaf cutting ant	Missouri

Apis mellifera	Honey bee	LBNL/Missouri	Server is available for ongoing annotation

Atta cephalotes	Leaf cutting ant	Missouri

Bombus impatiens	Eastern bumble bee	Missouri	Used internally to test deployment

Bos taurus	Cow	Missouri	Used internally; new assembly in progress

Cardiocondyla obscurior	Ant, tramp species	Missouri	Community is currently annotating

Monodelphis domestica	Gray, short-tailedopossum	Missouri	Server is available for ongoing annotation

Pogonomyrmex barbatus	Red harvester ant	Missouri	Community is currently annotating

Varroa destructor	Varroa mite	Missouri	Computational gene prediction has begun

Wasmannia auropunctata	Electric ant	Missouri	Community is currently annotating

Pungitius pungitius	Nine spine stickleback	Utahe	Analysis in progress

Over 40 species	Pigeons	Utah	Analysis in progress


Characteristic	Adjusted Odds Ratio (95% Confidence Interval) for Remaining Uninsured for Entire Year

Child uninsured >6 months at baseline	3.8 (1.4, 10.3)

African-American/black race/ethnicitya	2.8 (1.1, 7.3)

Male child gender	2.4 (0.97, 5.8)

Primary caregiver employed	0.5 (0.2, 1.4)

Child born in US	0.2 (0.01, 3.7)

Combined annual family income below federal poverty threshold	0.4 (0.1, 1.4)


	Density (kg/m3)	Thermal conductivity (W/(m °C))	Conductivity (S/m)	Specific heat capacity (J/(kg· °C))

Myocardium	1200	0.55	0.222	3200

Blood	1000	0.543	0.667	4180

Radiofrequency electrode	21,500	71	4,000,000	132


FGD	Age range at point of FGD	Mean age	No of participants	Male	Female	SCT	CT

FGD 1	13–15	13.5	6	4	2	4	2

FGD 2	15–17	15.7	7	2	5	5	2

FGD 3	19–24	21	7	4	3	2	5

FGD 4	16–20	18	5	2	3	2	3